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High-Throughput, Whole-Genome Sequencing
Abstract
Since the completion of the Human Genome Project, research focusing on the consequence of known human
genetic code has advanced by leaps and bounds. The development of personalized medicine, a field focused
on enumerating the effects of individual genetic variations, termed SNPs, has become a reality for those
researching the molecular basis of disease. With clinical correlates between genotype and prognosis becoming
ever more common, the utility of personal genetic screening has become impossible to ignore. In this report,
we present PennBio: a whole-genome sequencing company utilizing a novel single-molecule, real time
sequencing-by-synthesis technology. Using unique zero-mode waveguides, which have revolutionized single-
molecule detection, individual enzymes polymerizing novel phospholinked fluorescence labeled nucleotides
can be observed as they sequence genomic template DNA. Modern optical techniques record these
fragmented sequences, which are then analyzed by highly efficient alignment algorithms. A personal genomic
code will ultimately allow consumers to be aware of their genetic predispositions as the medical community
continues to discover them.
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Abstract 
 
Since the completion of the Human Genome Project, research focusing on the 
consequence of known human genetic code has advanced by leaps and bounds. The development 
of personalized medicine, a field focused on enumerating the effects of individual genetic 
variations, termed SNPs, has become a reality for those researching the molecular basis of 
disease. With clinical correlates between genotype and prognosis becoming ever more common, 
the utility of personal genetic screening has become impossible to ignore. In this report, we 
present PennBio: a whole-genome sequencing company utilizing a novel single-molecule, real 
time sequencing-by-synthesis technology. Using unique zero-mode waveguides, which have 
revolutionized single-molecule detection, individual enzymes polymerizing novel phospho-
linked fluorescence labeled nucleotides can be observed as they sequence genomic template 
DNA. Modern optical techniques record these fragmented sequences, which are then analyzed by 
highly efficient alignment algorithms. A personal genomic code will ultimately allow consumers 
to be aware of their genetic predispositions as the medical community continues to discover 
them.
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I.     Human Genomics 
 
 Traditionally, the clinical research at the heart of modern evidence-based medicine has 
been performed across large patient populations. While great efforts are undertaken to ensure 
that these sample groups are homogeneous, the confounding effects of individual variations are 
impossible to avoid and particularly difficult to model, imbuing the conclusions of any study 
with an often-significant degree of uncertainty. Rare conditions that affect only a small portion 
of the population, or that are not easily identified through clinical observation, are most prone to 
such mischaracterization – the very conditions that require the most specialized treatment, and 
lead to the most morbid outcomes. Physicians and their patients are ultimately tasked not only 
with assessing the likelihoods of these rare events, but also with evaluating the applicability of 
available evidence to the specific situations at hand. The unfortunate consequences of a chance 
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misjudgment are commonly seen in adverse drug reactions, treatment inefficacy, and late-stage 
disease detection. 
Over the past few decades, however, the rapid growth of genomics as a medically 
relevant discipline has been the catalyst for dramatic advances in the practice of molecular 
diagnostics. Through a greater understanding of how DNA is interpreted (transcriptomics) and 
how its protein products affect cellular processes (proteomics), scientists are, for the first time, 
beginning to associate abnormal physical conditions with their genetic precursors. This clinical-
to-genomic mapping paves the way for a new diagnostic and prognostic paradigm – the idea of 
personalized medicine. Recent translational research into the molecular basis for complex and 
widespread diseases such as cancer, heart disease, and diabetes has demonstrated the 
effectiveness of this approach. The physician now makes informed decisions based on the 
patient’s genetic make-up rather than population-average data, allowing for increased confidence 
and more favorable outcomes, overall.  
One of the most visible products of personalized medicine has been the field of 
pharmacogenetics, which seeks to characterize the interplay between individuals’ genotypes and 
their responses to specific medications. Therapeutic parameters including dosage, side effects, 
and efficacy can be predicted based on genomic data, allowing for the tailoring of an 
individualized treatment regimen. The field of pharmacogenetics also sees the potential of more 
rapidly identifying novel drugs for common use in humans.1 An example of the successful 
application of pharmacogenetic principles is the use of warfarin. Warfarin is an anti-coagulant 
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used in treating thrombosis, and is the most widely used anti-coagulant used in North America.2 
Its utilization, however, is limited by potentially severe adverse reactions to the drug. Genetic 
variations in the genes CYP2C9 and VKORC1 have been shown to be correlated with these 
dangerous side-effects. With this novel research, new statistical models involving age, weight, 
gender, and genotype are used to gauge dosage for individuals being prescribed warfarin.3 
 Cancer treatment has long used genetic strategies in the assessment of an individual’s 
stage of tumerogenesis, enabling the selection of more effective treatment regimens. This early 
form of personalized medicine is growing rapidly as techniques for characterizing the genetic 
aberrations present in the cancer cells become more easily performed. Cancers, in general, are 
defined by cells which have lost control of their genetic regulators, largely due to somatic 
mutations, allowing them to proliferate unchecked. These mutations can vary even within certain 
types of cancer, and the field of cancer genetics seeks to correlate the genetic mutations to 
prognostic outcomes. With genetic screening of the cancer being targeted, physicians can start to 
make prognostic and therapeutic decisions which more accurately suit the specific mutations 
which have occurred. 4,5 
An example of this customized treatment based on characterized oncogenesis is the 
prescription of Gleevec in the treatment of chronic myeloid leukemia (CML). Some 95% of 
CML cases are genetically characterized by a fusion of the BCR and ABL genes, forming the 
BCR-ABL fusion protein. Gleevec targets the ABL kinase activity, and is an effective treatment 
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for those with the BCR-ABL translocation, making genetic testing and often-used a diagnostic 
test in treating CML.6 
The application of genetic screening to treat cancer goes beyond the acute stage of the 
disease. Several types of cancer, called familial cancers, are passed down through generations 
from parent to child, and account for 5-10% of cancers seen in current oncology wards. Genetic 
screening can assess an individual’s risk, given that the genetic mutations associated with a 
certain disease have been characterized. With this knowledge at hand, preventative measures can 
be taken to minimize the chance of the oncogenesis. Mutations in the BRCA1 and BRCA2 genes, 
for example, are associated with increased risk of developing certain breast and ovarian cancers. 
Discovery of a high-risk mutation in one or both of these genes may prompt an individual to seek 
prophylactic treatment such as mastectomy or removal of the ovaries.7  
Oncology is not the only medical field which can benefit from the development of 
personalized medicine-based preventative treatment. Conditions such as heart disease, diabetes 
and other complex syndromes such as high blood pressure and high cholesterol have been shown 
to have significant genetic corollaries. Though both type I and type II diabetes are both suspected 
of having genetic correlations, type II shows much stronger hereditary influence. Several genes 
have been shown to be associated with the development of type II diabetes and their genetic 
variations are being more specifically characterized as research continues. 8,9  
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Personalized medicine is the new frontier in medical research, and in clinical practice. 
From acute treatment decisions based on the molecular basis of disease to preventative medicine 
based on pre-onset genetic screening, the potential benefits to society of continued genetic and 
translational research are immeasurable. 
I.1  Current Screening Methods 
 
 Contemporary genetic testing services – such as 23andMe and Navigenics – provide 
interested consumers with information about known biomarkers, that is, physically relevant 
genetic abnormalities. Numerous traits from eye color to predisposition for certain diseases to 
body types can be predicted with varying degrees of confidence. These services do not attempt to 
sequence the individual’s complete genome; instead, they identify single-nucleotide 
polymorphisms (SNPs – pronounced “snips”) in which certain markers are exclusively targeted. 
23andMe, for example, offers 500,000 SNPs associated with 109 traits at $399 per individual. 
This gives the consumer price to be 0.08 cents per SNP and $3.67 per trait. 
Databases such as NCBI’s dbSNP have been established to catalogue the continuously 
growing number of reported SNPs discovered in current biomedical research. As of April, 2009, 
the dbSNP had over 16,600,000 SNPs identified with many millions added every six months, but 
few of these have been cited clinically and even fewer have been identified with definite 
phenotypes. These databases, however, are science intensive, and would intimidate anyone not 
extraordinarily familiar with molecular genetics, and the consumer is undoubtedly more 
concerned with their phenotype – disease predispositions, for example – than their actual 
H u m a n  G e n o m i c s  
 
 
8 
 
genotype – that base 53,457 in their HOXA9 gene is an adenine. Websites such as SNPedia.com 
seek to connect clinical correlates to known SNP variants. SNPedia.com currently offers clinical 
phenotypic correlates on 5,043 SNPs, covering 307 traits, and is growing steadily.  
The limitation of these services lies in the fact that an estimated 10% of the 100 million 
SNPs predicted to be present in the human genome have been identified, and an even smaller 
fraction of those have been associated with some known physical manifestation.10 The SNP-
focused genomics products therefore become obsolete as new discoveries are made, as they are 
restricted in their usefulness to SNPs that were known at the time of the analysis. Whole-genome 
sequencing operations offer a comprehensive genomic sequence which will be clinically relevant 
for the rest of the consumer lifetime. By delivering an entire genomic sequence, the customer has 
been granted access to at least 16 million known SNPs, and over 5,000 correlated SNPs which 
make them who they are.  
I.2  The PennBio Approach 
 
PennBio is a newcomer to the biotechnology industry committed to providing 
exceptionally accurate whole-genome sequencing. The primary goal of the project is to achieve 
unprecedented genome throughput at a low cost.  Specifically, operations have been designed to 
meet an estimated demand for 3000 human genomes per year at a cost of $10,000 or less, with a 
maximum start-up cost not to exceed $25 million.  The rapid production and low price targets 
were inspired by the Archon X Prize competition, which offers a $10 million award to the first 
team to be able to meet these specified goals.   
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A brief overview of the PennBio business plan is presented below in Table I.1, providing 
an outline of the goals, scope, deliverables, and timetable for developing a system for high 
throughput genomic sequencing.   
Table I.1  Project Charter for High Throughput Genomic Sequencing  
Project Name PennBio: High-Throughput Genomic Sequencing 
Project Champion Dr. John Crocker 
Project Leaders Gregory Bittle, Boris Petkov, Evan (Yonghee) Rhee, and Elliot Woods 
Specific Goals Sequence 3000 human genomes per year for no more than $10,000 per genome sequenced, and with a start-up cost of $25 million or less. 
 
Project Scope 
 
In-Scope: 
 
à Identify and evaluate high-throughput sequencing techniques 
 
à Apply the  most promising technology to provide in-house whole-
genome sequencing  
 
à Characterize the biological, optical, and computational methods 
underlying this technology 
 
à Select appropriate equipment and staff 
 
à Develop a viable business model, centered around the above 
production level, investment, and a genome price 
 
Out-of-Scope: 
 
à Manufacturing of Zero-Mode Waveguides (ZMWs) 
 
à Focused screening (such as SNP screening) 
 
à The provision of genetic counseling or medical advice 
 
Deliverables 
 
à Market assessment and competition analysis 
 
à Technical feasibility assessment 
 
à Full scale manufacturing requirements and protocol 
 
à Financial analysis over a 5-year project life cycle 
 
Timeline 
 
à Working sequencing prototype within 12 months  
 
à Scale-up operations within 2 years 
 
à Full-scale production in years 3-5 with concurrent R&D 
 
à Liquidate or sell the company at the end of year 5 
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The scope of the project includes all processing steps from DNA isolation to complete 
genome reassembly. Once extracted, the DNA will be analyzed by single-molecule real time 
observation, a highly efficient approach at sequencing that reads code as transcription occurs, as 
opposed to the original Sanger method, which requires the amplification of the DNA prior to the 
reading of sequence. The technique adopted for the process closely models that proposed by 
Pacific Biosciences, who uses specially developed zero-mode waveguides (ZMW) and uniquely 
labeled fluorescent nucleotides. These nucleotides will be produced on-site, as there are no 
vendors that produce these specific molecules.  
The production of the ZMWs, however, will be contracted out to a nanofabrication firm 
in order to avoid the high capital investment in lithography equipment. Additionally, PennBio 
will not offer any forms of genetic counseling of genome interpretation. This is a rapidly 
evolving, research-intensive service that is best left to specialists.   
The goal of the first year of the product development is the production of a working 
sequencing prototype.  Once the effectiveness of the prototype is verified, scale-up and 
commercial sequencing will begin in year two.  The number of setups will be increased so that 
the desired throughput for meeting the project goal can be met.  Following year two, most of the 
company resources will be dedicated to full time commercial genome sequencing and research 
and development for the next innovation in genomic sequencing. 
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I.3  Technology Readiness Assessment  
 Following the very first successful genome sequencing, each of the next attempts at 
human genome sequencing strived toward reducing costs and increasing throughput.  With the 
Archon X Prize setting the desired bar for motivation to achieve the set requirements, the 
necessary technology has to first develop in order to support the ultimate goals.   
 
 
 
 Figure I.1 Innovation map for high-throughput genomic sequencing  
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 With improvements in nanostructure fabrication, novel nucleotide chemistry, genomic 
assembly algorithms, and optical devices capable of single molecule detection, PennBio is able 
to offer sequencing which meets lofty throughput and price goals never before reached using the 
SMRT chip platform.  The technique requires a relatively low reagent volume, reducing costs 
significantly when compared to now-obsolete sequencing methods. Additionally, the throughput 
is maximized as the DNA sequence is read while transcription occurs.  In order to carry out 
SMRT chip-based sequencing, the key supporting technologies of zero-mode waveguides 
(ZMWs), novel fluorescent molecules, and powerful imaging instrumentation have to be 
available first (See Figure I.1).  Due to advances in material sciences, techniques to cheaply and 
consistently produce ZMW chips make them readily available at the desired specifications.  In 
addition, developments in fluorophore synthesis allows the production of the key sequencing 
molecules in lab.  Possibly the most important development for SMRT sequencing in terms of 
throughput is the development of Electron Multiplying Closed-Coupled Device cameras or 
EMCCDs.  The cameras allow for high resolution imaging at high frame rates necessary for the 
real-time reading of massive parallel arrays of microreactors that are the key parts of SMRT.  
Further improvements to this imaging technology would only serve to increase the throughput of 
the sequencing techniques.   
  
Figure I.2  Organization of the sequencing process
At $4,000 per individual, PennBio
than ever before offered: for an estimated 0.02 cents per SNP. More importantly, as new SNPs 
are discovered and new clinical correlates are published, the 
information necessary to re-examine his or her
Customers of SNP-limited services, such as 
they hope to maintain an up-to-date 
susceptibility. 
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 is offering a superior and more comprehensive service
PennBio customer will have the 
 genome under the guidance on a genet
23andMe, will have to be retested in the future if 
genomic perspective on their current health and disease 
 
 
 
 
icist. 
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I.4  Customer Requirements  
 The two main customer requirements in designing the high throughput genome 
sequencing technique are high throughput and reading accuracy.  In order to meet both of these 
customer requirements, “New-Unique-Difficult” (NUD) concepts must be implemented.  These 
are addressed by critical to quality variables (CTQ) that define the core of the SMRT technology.   
The main limit on this throughput is the resolution capabilities of the EMCCD in use and 
the frame rate of the EMCCD at the said resolution.  As resolution of the EMCCD increases, the 
frame rate of the camera decreases.  SMRT technology relies on recording the necessary 
chemical reaction in real time.  Therefore, the more reactions that can be seen by the cameras, 
the higher the throughput obtained.  The number of reactions that are viewed is also dependent 
on the waveguide chip itself.   
Customer 
Requirements   CTQ Variables Weight 
Reading Accuracy 
 Polymerase Error Rate 
0.25  EMCCD Frame Rate 
 Number of Waveguides 
High Throughput 
 EMCCD Resolution 
0.75  
EMCCD Frame Rate 
 Number of Waveguides 
 Rate of Reaction 
Table I.2 Customer Requirement This table describes the customer requirements that are met by 
SMRT sequencing technology, and the CTQ variables that address the specific customer requirements.   
H u m a n  G e n o m i c s  
 
 
15 
 
Since the reaction occurs on the waveguide chip, increasing the number of reaction 
locations on the ZMW increases throughput capabilities.  Additionally, running the reaction as 
fast as possible maximizes the throughput.   
In order to successfully view the reaction while maintaining reading accuracy, it is 
important to maintain an EMCCD frame rate that can match the speed of the reaction.  More 
specifically, the frame rate of the camera must be greater than the rate of the reaction observed in 
each well.  A compromise must be reached between the frame rate of the camera and the 
resolution that is used in order to maintain the throughput and reading accuracy, while keeping 
Table I.2 in mind.  Throughput and reading accuracy are in fact very tightly bound.  In addition 
to the compromise between EMCCD speed and resolution, the coverage of the process must be 
addressed.  Increasing the coverage, or amount of times the whole genome is read increases the 
reading accuracy.  However in order to meet this coverage requirement, the throughput must also 
increase.  Therefore, factors such as waveguide number and EMCCD specifications that increase 
throughput are directly bound to increasing reading accuracy as well.   
I.5  Unprecedented Throughput 
 
Single-day turnaround is one of the hallmarks of the SMRT sequencing design, and plays 
a vital role in setting this technology above the competition.  For a given investment in detection 
equipment, the limit of EMCCD efficiency is achieved by one-to-one waveguide to pixel 
mapping. 
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 The maximum number of waveguides that can be simultaneously observed (nZMW,max) is 
therefore defined by the EMCCD camera’s field of view: 
,max 512 512 262,144ZMWn = × =
 
Equation I.1 
Some of these pixels will be used to detect a bright pattern to which the nanopositioning stage 
can align itself, and a margin of error in the alignment will be allowed. Assuming the pixels at 
the extreme edges of the field of are not involved in sequencing, the actual number of ZMWs 
under observation (nZMW) is: 
262,144 (4 512) 4 260,100ZMWn = - × + =
 
Equation I.2 
 Not all of these waveguides will ultimately contain DNA polymerase molecules; rather, 
the proper immobilization of an enzyme within a ZMW is a Poisson event. The probability of 
single-occupancy (the only fill state that will produce a meaningful signal) achieves its 
maximum at 36.8% when λ = 1. Therefore, the number of polymerase molecules that should be 
applied to the chip in order to maximize single-occupancy is: 
29 29
29
1
260,100
260,100
phi phi
ZMW
phi
n n
n
n
l = = =
=  
Equations I.3, 4 
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Assuming only 36% single-occupancy is achieved, the number of active ZWMs would be: 
, 260,100 0.36 93,636 active waveguidesZMW actn = × =
 
Equation I.5 
 The polymerization rate of phi29 has been demonstrated to be no less than 4.7 bases per 
second13. At this speed, the number of bases synthesized per second, per SMRT chip is: 
93,636 4.7 440,089 bp/sbpn s = × =
 
 
Equation I.6 
This process must be sustained until a 9-fold multiplicity is generated, that is, until the total 
sequenced length is equal to nine time the length of the genome, or 27 gbp. As we will 
demonstrate in Chapter V, such redundancy is necessary if gaps are to be avoided. The time 
necessary to accomplish the coverage goal is equivalent to the time required to sequence a single 
human genome on a single SMRT chip, and is calculated to be: 
9 10(3 10 )(9) 2.7 10 1(6135 s) 17.0 hr
440, 089 3600 s/hrbpn
s
´ ´ æ ö= = × =ç ÷æ ö è ø
ç ÷
è ø
 
 
Equation I.7 
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The SMRT system is the only available genome sequencing platform that offers such low 
turnaround times, without compromising quality or volume. The waveguide array not only serves 
to attenuate background noise, but it also provides the geometric precision required for efficient, 
single-pixel detection. Combined with a purpose-developed polymerase and powerful computing 
resources, this novel sequencing technology is certainly the most promising among modern 
whole-genome techniques. In the next chapter, the advantages of SMRT technology will be 
examined. 
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II.    The SMRT Chip Platform 
 
Pacific Biosciences was founded in 2004 with the goal of developing a low cost, high-
throughput genomic sequencing system driven by the observation of single DNA polymerase 
molecules, working continuously under realistic biological conditions11. By monitoring hundreds 
of thousands of enzymes in parallel, this technique is distinguished by exceptional sequence data 
quality and unprecedented throughput.  
 These capabilities are due in large part to “single-molecule real-time” (SMRT) 
technology, which is itself a fusion of biochemistry, optical theory, and recent advances in 
nanofabrication12. The physical product of SMRT technology is the SMRT chip – a single-use 
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assay platform that makes the high-fidelity, high-parallel reads possible. Two of the most 
common challenges to successful fluorescence-based assays—contiguous long sequence reads 
and negligible fluorescent noise—are simultaneously overcome by this revolutionary design, 
which for the first time utilizes zero-mode waveguide reaction vessels and phospho-linked 
fluorescent nucleotides to obtain a high-multiplex, high signal-to-noise output of long DNA 
sequences.  
 
Figure II.1  SMRT chip with array-separation gasket (A) Macroscopic view of a waveguide array (B) Closer view – 
the bright spots are flaws in the aluminum cladding (C) SEM characterization of a single cylindrical waveguide (D). 
 
 
II.1  Sequencing by Synthesis 
 
 Using zero-mode waveguides (ZMW)—small aluminum wells in the bottom of the 
reaction vessel which have apertures smaller than the wavelength of the biomolecules’ 
fluorescent emissions—signal to noise ratios become dominated by the presence or absence of 
those molecules in the waveguide—see Figure II.2. Utilizing this technology, single 
biomolecules can be observed in action. The concept behind single molecule real-time (SMRT) 
sequencing relies on the interplay between active DNA polymerases, synthetic nucleotides, and 
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the zero-mode waveguides. With some preparation, these waveguides can be populated by single 
DNA polymerase enzymes immobilized in place at the bottom of the wells13. 
 
 
Figure II.2  ZMW with active polymerase. Reproduced from Eid (2009). 
  
DNA polymerases replicate DNA polymers by using single stranded DNA template 
polymers and synthesizing a complementary strand using free DNA monomers known as 
nucleotides, matching guanine to cytosine and adenine to tyrosine and vice versa. SMRT 
sequencing relies on replacing natural nucleotides with synthetically labeled fluorescent 
nucleotides. These nucleotides are fluorescent until the DNA polymerase incorporates them into 
the ever-growing complementary strand. Once incorporated, the fluorescent tag is released from 
the nucleotide, leaving it ‘dark’. When immobilized DNA polymerases bound to template DNA 
incorporate these synthetic nucleotides into a growing complementary strand at the bottom of the 
zero-mode waveguides, fluorescent emissions from the nucleotides escape the waveguide only as 
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they are being incorporated into the complementary strand then go dark as their fluorescent 
moiety is cleaved and diffuses from the waveguide. By labeling the four different bases with four 
distinguishable fluorescent tags, emissions from the waveguide form a temporal sequence of 
different wavelengths which directly reflect the sequence of the strand being synthesized and 
therefore the sequence of the template strand – see figure II.3. These emissions can be recorded 
with high resolution optical devices and the sequences stored for data analysis.  
 
 
Figure II.3  Sequencing by synthesis process, showing nucleotide addition (1), fluorescent emission and 
fluorophore cleavage (2, 3), followed by polymerase procession and addition of the next base (4, 5). The intensity 
time trace is representative of time-series data generated upon signal analysis. Reproduced from Eid (2009). 
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II.2  The Zero-Mode Waveguide 
 
Existing methods for single-molecule detection, such as 
fluorescence correlation spectroscopy and near-field confocal 
microscopy, are characterized by observation volumes on the 
order of femtoliters (10-15 liters)14. If any specific individual 
molecule is to be identified with any certainty, then any 
additional fluorescent species may not be present above pico or 
nanomolar concentrations. While this background-minimization 
technique is effective, the use of unusually low ligand concentrations in an enzyme-based assay 
can have undesirable effects on reaction kinetics, or even cause the reaction pathway to deviate 
from its natural course. DNA polymerase, in particular, has a micromolar Michaelis-Menten 
constant (Km), exhibits prohibitively slow polymerization rates at low nucleotide availability. 
The zero-mode waveguide (ZMW) addresses this limitation by dramatically reducing the 
observation volume, thereby allowing the use of biologically-relevant conditions.  
For light of any given wavelength, an aperture can be constructed through with this light 
cannot propagate15. The aperture can take on any number of geometries, and its dimensions are 
functions of the wavelength of the incident radiation. The cylindrical ZMWs on the SMRT chip 
are designed to be narrower than this cutoff diameter, so that the fluorophore excitation radiation 
becomes evanescent upon entering, and decays exponentially with distance traveled into the 
ZMW. In this way, the emission energy profile is sufficient to excite any fluorophores at the very 
 
     Figure II.4  An illustration of a  
cylindrical ZMW. Published by 
Pacific Biosciences, Inc. (2008). 
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edge of the waveguide, but too weak to excite the fluorescent 
species in the solution above. Attainable observation volumes 
are decreased from femtoliters to zeptoliters (10-21 liters), 
which provides a margin to increase fluorescent species 
concentration without contributing appreciably to 
background. 
With this knowledge of the incident energy profile, a 
single DNA polymerase molecule is immobilized at the 
bottom of each waveguide – precisely within the volume 
under observation. As this enzyme adds fluorescently labeled 
nucleotides to a template sequence, it brings them within the 
observation volume, and an excitation signal is detected. The 
time required to add a nucleotide to a growing strand is several 
orders of magnitude greater than the diffusing timescale of these molecules, enabling the 
polymerization process to be clearly monitored over the constant, but low intensity, noise13.  
SMRT chip production is very similar to integrated circuit fabrication, and makes use the 
many of the techniques developed for this industry. With even more recent improvements in the 
reliability and miniaturization of the manufacturing equipment, it has become widely available, 
and the process used in zero-mode waveguide creation is now quite routine. Given the submicron 
Figure II.5 A heat map of illumination 
intensity (top frame). Intensity as a 
function of distance into the ZMW by 
radius (bottom frame). Reproduced 
from Levene (2003). 
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scale of the waveguides, an array density on the order of 106 waveguides per mm2 is easily 
achieved, enabling extensive parallelization of the sequencing process. 
II.3  Phospholinked Fluorophores 
 
 Sequencing techniques utilizing fluorescently labeled nucleotides are well documented 
and have been robust strategies for sequencing; however these approaches have used almost 
exclusively base-linked nucleotides which present many enzymatic incorporation problems 
including processivity issues and overall protocol encumbrance as additional bleaching or 
washing steps are necessary for longer reads.16 Not only do base-labeled nucleotides form an 
altered complementary strand, which is sterically disturbed—leading to issues such as increased 
dissociation events from the enzyme (lowered processivity), these steric issues also lead to active 
site association issues leading to extremely hampered enzymatic kinetics. In addition, these 
fluorescent tags also remain on the growing complementary strand leading to increasing 
background noise levels unless bleaching steps are taken to eliminate previously incorporated 
bases from the fluorescent read-out. These additional steps interrupt enzymatic activity and these 
techniques are therefore characterized by relatively short read-lengths as dissociation events 
become much more frequent. To address this issue, when considering high-throughput entire 
genomic sequencing, an alternative approach was developed using phospho-linked fluorescently 
labeled nucleotides which eliminates the issues associated with base-linked fluorophores. The 
phosphodiester bonds of nucleotides are cleaved when the nucleotides are incorporated into the 
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growing complementary strand, and phospho-linked fluorophores diffuse away as the cleaved 
phosphate groups do.  
 
Expected Throughput   In practice process times not equal to 24 hours would lead to undesirable precession in the sequencing time over a period of several days. In order to keep the work schedule constant, 24 hours must be allotted for sequencing.  The throughput goal is 100 genomes per 10 days, which is equivalent to 3000 genomes per year.  Given the constraint presented above, and assuming five “sequencing days” per week, the number of stations/chips required is: 
(10 genomes/day) 0.8 13 stations
(1 genomes/(day station))stations
n ×= =
×  
 
Equation II.1 
 
Each of these stations will consist of one SMRT chip, simultaneously observed by two EMCCD cameras through an inverted fluorescence microscope. 
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III.    Competitive Analysis 
 
 The relatively new market for genomic sequencing is filled with opportunity for growth; 
however, this opportunity opens up possibilities of competition.  In order to move forward with 
the business model for PennBio, it is critical to perform an analysis of the competitive 
environment and the major companies that offer similar services with slightly different 
techniques.  Besides the SMRT technology used for PennBio’s design, three other competing 
technologies have been analyzed.  The companies offering these technologies are Illumina, 454 
Sequencing, and VisiGen.  Since genome sequencing is a relatively new market and most of the 
products being offered are still in their infancy, not all of the information regarding the products, 
such as potential costs, is available to the public.     
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III.1  Illumina 
 Illumina relies on Solexa technology in order to sequence their 
genomes.  The basis of the sequencing involves fragmenting the genome 
into pieces and then attaching adapters to the end of each strand.  These 
adaptors attach to a flow cell surface.  Once the strands are attached to the 
surface, they undergo many cycles of amplification until they form 
clusters of up to 1000 identical copies.  These copies are all single 
stranded.  Following this step, fluorescently tagged dNTPs with reversible 
termination properties are added along with polymerase.  These attach to 
the end of the strands and are then emit light following laser excitation.  Illumina’s imaging 
technology then reads out the different wavelengths emitted for each nucleotide.  This process is 
repeated again until the entire strands are read.  Then the fragments are assembled into a genome 
sequence using an unreleased algorithm.17,18  
 One of the advantages of the Illumina 
technology is the simplicity of the flow cell design. 
There are no specific wells or beads that need to be 
attached to, and the amplification of the clusters 
allows for a large viewing concentration.  The very 
nature of the clusters themselves guarantee a strong 
Figure III.1  Illustration of 
the DNA fragment clusters 
attached to the flow cell.13  
Figure III.2  The Illumina Genome Analyzer12 
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signal, as they are very concentrated as opposed to the single fluorescent molecule that has to be 
detected for the PennBio design.  Also, the optics of the system are much simpler, since the 
molecules are placed arbitrarily.  A major advantage that lllumina posses is an already built 
sequencing station that mechanizes each sequencing step.  These units will be provided to 
laboratories, so that Illumina does not actually sequence the genomes, but the labs that purchase 
them do.   
 A major disadvantage to the technology is that it has low throughput compared to 
PennBio’s projected throughput.  An entire genome can be sequenced on the order of weeks.  
This is just the sequencing method.  The actual preparation of the flow cell and amplification of 
the DNA takes one business day.  This is significantly longer than PennBio’s expected 
throughput.     
III.2  454 Sequencing 
 454 Sequencing is more competitive than Illumina in terms of 
throughput, though not by much.  Like Illumina, 454 amplifies a single 
stranded molecule attached to a surface.  However, the surface is a bead 
that is immersed in an emulsion, creating a microreactor.  These beads 
are then placed in individual wells.  The wells are in a PicoTiterPlates 
that are found in a Genome Sequencer FLX Instrument.  Using a fluidic 
assembly, the sequencer pumps nucleotides over the wells.  Upon incorporation with the DNA 
template, a combination of fluorescent enzymes that react with the template emits different light 
Figure III.3  454’s 
bead microreactor.14 
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spectrums based on the nucleotide.  Much like the other sequencing techniques discussed, the 
light emitted is used to come up with a sequence reading.  Unlike the rest of the techniques, the 
454 technique adds each dNTP one at a time per cycle, and these cycles are repeated until the 
entire DNA strand is sequenced.  With DNA fragments of approximately 400 bp long, the 
cycling slows down the sequencing time.19   
 In addition to this delay, the relatively short fragment length, increased time is required to 
process and reassemble the genome.  As it is discussed later, in the section dealing with 
reassembly of the genome, shorter fragment lengths make it much more difficult and time 
consuming to assemble a complete genome from fragments. 
III.3  VisiGen 
 VisiGen is the competitor most similar to PennBio.  
VisiGen uses SMRT sequencing in order to achieve their 
high throughput.  The major difference between the two 
competing technologies is PennBio’s use of a zero-mode 
waveguide.  VisiGen forgoes the use of this plate and 
randomly immobilizes its polymerase onto the surface of 
its plate.  The biomechanism for both companies use a 
polymerase that allows DNA to replicate with the addition 
of fluorescently tagged dNTPs.  Using laser excitation, the Figure III.4  Basic setup for the 
VisiGen sequencing system.15 
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fluorophores emit light that is detected by an EMCCD camera, as can be seen in the figure on the 
left.20   
 Using this technique, VisiGen avoids the requirement for waveguide use.  Though this 
reduces the cost in purchase of waveguides, it creates several other problems.  With the 
polymerases randomly dispersed with no real separation, interference from other complexes 
creates potential errors in the sequence read and increase the signal to noise ratio.  In addition to 
this, the field of view used is not maximized, as the polymerases do not necessarily line up with 
each pixel, as they do in the ZMW for PennBio.  As seen in Figure III.4, VisiGen uses a Bayer 
color filter on its EMCCD.  This dedicates at best 4 pixels per polymerase, which is half of the 
resolution used by PennBio, as it is discussed later.  This increases the number of microscopes 
required per station or the number of stations required per genome to be sequenced, increasing 
the cost well above any savings incurred from not having to purchase waveguides.    
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IV.    DNA Polymerization 
 
 The following chapter seeks to describe in detail the synthesis reaction contained by each 
ZMWs. In order to understand the process, some fundamental biochemistry must be discussed. 
 To fully conceptualize the reaction taking place, let us begin by considering the reactants, 
themselves. In sequencing-by-synthesis, single stranded template DNA serves as the foundation 
of the reaction. It is given the name template because it serves as a guide for the synthesis of new 
strands, and DNA’s unique structure makes it ideally replicated by a process so elegant, it could 
only be found in nature. 
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 DNA’s famous double-helix structure is constructed of two anti-parallel strands of 
nucleic acid polymers made from deoxynucleotides. The strands have a backbone made from 
connecting ribose and phosphate ester linkages labeled from 5’ to 3’ from the carbons on the 
ribose ring, like the sides of a ladder, in which the rungs are the nucleobases—guanine, adenine, 
cytosine, and tyrosine. The rungs are formed as hydrogen bonding between complementary bases 
connects the two phosphor-deoxyribose backbones. Adenine interacts with tyrosine as guanine 
pairs with cytosine—see Figure IV.1below. 
Figure XII.1  DNA's unique ladder-like structure. Detailed are the phosphate-deoxyribose backbone and 
the hydrogen-bonded nucleobases complementary to one another. Reproduced from Ball (2007). 
D N A  P o l y m e r i z a t i o n  
 
 
35 
 
 
This unique structure allows DNA to be denatured—when the hydrogen-bonding 
between complementary strands is disrupted and the two strands are separated from one 
another—and then new complementary strands synthesized from the two original strands, 
effectively doubling the number of strands each time. Because the bases in the double-stranded 
DNA are complementary to each other, each strand holds the entire code, and both strands can be 
used to make entirely new, complete double-stranded DNA. In vivo this process involves a 
complex interplay between many enzymes which serve distinct functional roles in constructing 
new complementary strands from the template strands. In vitro, this process can be modified to 
take place with the help of just one enzyme—DNA polymerase. DNA polymerase catalyzes the 
addition of nucleotide triphosphates to a growing complementary strand by cleaving the 
phosphate groups from the substrate. Polymerases, however, cannot construct complementary 
strands de novo.  They must bind double stranded DNA and build upon the complementary 
strand in so-called extension reactions. To ready template strands for replication in vitro, 
therefore, template strands are primed with short, single stranded DNA polymers complementary 
to the beginning of the sequence to be replicated—these short nucleotide sequences are called 
primers. Once primed the polymerase adds the complementary nucleotide, shifts down the DNA 
and adds the next complementary nucleotide. Once the polymerase reaches the end of the 
template strand, the polymerase dissociates from the newly synthesized double stranded DNA 
and can complex with a new, primed template strand. This concentric-cycles scheme for DNA 
synthesis is detailed in Figure IV.2.  
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Figure IV.2  In vitro DNA replication using primers to allow phi29-polymerase complexing and extension of the 
complementary strand. 
 In order to utilize this invaluable enzymatic machinery to sequence template DNA by 
synthesis, several steps must be taken to prepare the reaction vessel and the starting materials. 
First, an appropriate DNA polymerase must be chosen which is suited to the task of accurate, 
speedy DNA replication in the manner necessary for SMRT sequencing. We show that the phi29 
polymerase, from the phi29 bacteriophage, is well suited for the job. Next, the template DNA 
must be prepared. Because an individual’s genome is to be the template for sequencing, a tissue 
sample is needed to obtain a sample of the DNA. Using a whole-genome amplification kit 
offered by Qiagen, a small amount of genomic DNA, which can be isolated from a non-invasive 
cheek swab, can be amplified so that plenty of genomic template is available for sequencing. For 
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the sequencing-by-synthesis reaction, suitable primers are chosen such that no sequence is biased 
over others, and that the entire genome is sequenced in its entirety. The templates, primers and 
polymerases are pre-bound and pre-complexed before immobilizing the polymerase into the 
zero-mode waveguides. This immobilization involves several chemical treatments of the 
waveguide nanostructure to ensure optimal waveguide occupancy. Lastly, the ingenious 
phospho-linked fluorescent nucleotides are discussed as their unique properties and behavior as 
substrates for DNA synthesis are crucial for the success of SMRT sequencing, followed by a 
discussion of dissociation rates for completed synthesized strands and reassociation of new 
primed-template strands, polymerization rates and error rates.  
 
IV.1  The Phi29 Polymerase 
 
The polymerase to be used in the SMRT system had to be chosen carefully. Dozens of 
polymerases are commercially available and most have been extensively documented. Most of 
these polymerases serve very specific roles: the Taq family of polymerases consists of thermally 
stable polymerases and these are ideal for polymerase chain reactions in which thermo-cycling is 
utilized to produce extremely high levels of amplification of template DNA; high-fidelity 
polymerases are available which contain extensive 3’->5’ exonuclease activity—essentially 
backward double-checking of synthesized strand—enabling the proof-reading of the strands 
being synthesized to give extremely low error rates in synthesized strands; long-template 
polymerases exist which are known for very high processivity – a sort of ‘polymerase endurance’ 
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– and very low dissociation rates between the polymerase and the template strand. These 
polymerases are capable of replicating very long template strands. 
The bacteriophage, phi29, is a member of a family of phages which mostly infect 
Bacillus subtilis, a ubiquitous bacterium commonly found in soil. This phage carries its genetic 
code in double-stranded DNA form, and its DNA polymerase has been found to be an 
exceptional one.21 Because of the nature of the phage’s minimal biochemical ‘luggage’ present in 
its capsule, its polymerase must be capable of replicating the genome of the phage with little of 
the enzymatic support often present in prokaryotic or eukaryotic systems. The phi29 polymerase 
has been found to be capable of extremely processive replication in the absence of accessory 
proteins to aid in the retention of the template strand in the active site of the enzyme. In addition, 
the polymerase shows strand displacement capabilities while it polymerizes making it able to 
replicate strands of DNA with complementary strands still partially bound to the template strand 
as well as overcome secondary structure in single-stranded DNA templates. These properties 
allow the enzyme to replicate the phage’s genome without the use of primases or other accessory 
proteins commonly found in genomic replication schemes and perform multi-pass replications 
without dissociation with the template with just one modestly sized (66.7 kDa) monomeric unit, 
further highlighting the incredible efficiency of this enzyme. 22  
In addition to incredible processivity – average replication lengths of over 70 kbp are 
commonly reported and values as high as several hundred kilobases have been cited in the 
literature – the synthesis rates and fidelity of the enzyme are also rather impressive. Esteban, 
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Salas and Blanco reported error rates as low as approximately 10-5 and polymerization rates as 
high as 100 bases per second.23,24,25  
In combination, these properties of the phi29 polymerase – extremely high processivity 
and strand displacement capabilities with very high replication fidelity and synthesis rates – 
make it an ideal candidate as the enzymatic machinery for the catalysis of isothermal single 
molecule DNA replication.  
 
IV.2  Target DNA Isolation 
 
 Genomic sequencing by synthesis relies on template genomic DNA. To isolate a sample, 
the REPLI-g whole genome amplification kit by QIAGEN utilizing multiple displacement 
amplification (MDA) with phi29 polymerase provides a simple and cheap method of DNA 
isolation and amplification.26 Only a cheek swab from the person whose genome is to be 
sequenced is needed providing a non-invasive means of collecting their genomic code. The 
cheek swab collects cells from the inside of the mouth which contain whole genomic DNA. The 
DNA is then isolated from the cells and amplified to ensure that enough material is present as 
described in Appendix B. As shown in Figure IV.3, the REPLI-g Midi kit provides 40 µg of 
genomic DNA, regardless of the amount of starting material. 
The amplified genomic DNA is generally greater than 10 kbp in length and ranges from 2 
to 100 kbp. And the REPLI-g Midi kit uses the same phi29 polymerase as the SMRT system, 
providing the same level of fidelity as is necessary for accurate sequencing. As with the SMRT 
system, the phi29 polymerase shows sequence displacement competency so that there is no 
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sequence bias in the amplification.27 These properties make the product of the genomic 
amplification a perfect template for SMRT sequencing.28  
 
IV.3  Priming and Random Hexamers 
 
With plenty of genomic DNA as a template for SMRT sequencing, the DNA must be 
primed for sequencing by synthesis. There is no known DNA polymerase which can replicate 
DNA from a native single strand. The phi29 polymerase requires a portion of the template strand 
to be double stranded as a starting point for synthesis, as it binds complementary nucleotides to 
the growing synthesized strand, so a starting synthesized strand must be bound to the template 
DNA before the reaction can begin. Choosing the right primer is an extremely important task. 
Because the entire genome must be sequenced, no one sequence can be biased over another. This 
demands the use of random hexamers.  
Figure IV.3  Yield of genomic template DNA after treatment with the REPLI-g Midi kit, as given by QIAGEN. 
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 Random hexamers, a collection of a six nucleotide oligonucleotides with random 
sequences—designated 5’-NNNNNN-3’—have been used in sequence-independent 
amplification for years and are well documented, widely available, common reagents for 
unbiased amplification of DNA.29,30 Because every possible combination of nucleotides is 
present in random hexamer mixes in essentially equimolar amounts, all sequences present in the 
reaction vessel have the same probability of being amplified. Fidelity Systems has developed a 
phi29 Random Hexamer mix optimized for sequence-independent phi29 polymerase-mediated 
DNA amplification, designed by Clyde A. Hutchison and colleagues, which includes random 
hexamers resistant to 3’->5’ exonuclease activity—a feature of some polymerases making them 
capable of rejecting imperfect priming—providing optimized hexamer-template association 
resistant to dissociation by phi29 polymerase-mediated exonuclease activity.31  
Template DNA amplified with the QIAGEN MDA kit is denatured using an alkaline 
denaturation as opposed to a heat denaturation for several reasons. First, phi29 polymerase is 
heat sensitive and is inactivated at temperatures above 65°C, while most thermocycling-based 
polymerization protocols include denaturation steps around 94-98°C. Therefore, annealing—the 
term given to the association of complementary sequences to form double-strands—of primers 
their templates is not possible without first inactivating the polymerase.  Second, heat 
denaturation is known to degrade DNA samples and fragmented makes for poor sequencing 
templates.  
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The preparation of the template-primer complex is as follows. The DNA isolated with the 
QIAGEN REPLI-g Midi kit is first sonicated to a mean length of 2kbp to eliminate steric issues 
associated with entry of the template-polymerase complex into the waveguides. Next, the 
sonicated template DNA is denatured using a 0.2 M NaOH alkaline solution. After alkaline 
denaturation, the template DNA is incubated with the primer mix at a concentration of 50µM for 
3-10min at 30°C.32  
 
IV.4  Template Binding 
 
Next, the primed template DNA is incubated at 1.5-3 molar excess with biotinylated 
phi29 polymerases at 4°C for ten minutes in buffer to form the template-polymerase complex.33 
Because no free nucleotides are present, the primed template DNA binds to the active site of the 
enzyme but the synthesis reaction does not proceed. The template-bound polymerase must be 
immobilized in the bottom of the waveguides for the synthesis reaction to be accurately observed 
and recorded. 
 
IV.5  Immobilization of the Enzyme-Template Complex 
 
Immobilization of the polymerase requires extensive preparation of the waveguide 
nanostructure. Several factors must be taken into consideration when preparing the 
nanostructure. Though circular ZMWs have been used in many single-molecule detection 
studies,34 their applications have been highly limited by the inability to selectively immobilize 
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molecules to the observation volumes immediately above the transparent floor. To address this 
issue, the dual-material nature of the ZMWs has to be exploited. Selectively reacting one of the 
two materials in a derivatization reaction enables the manipulation of either of the two different 
surfaces. Many factors had to be taken into consideration when designing the derivatized surface: 
stability in aqueous solution, in which the sequencing reactions would take place is a high 
priority; fluorescent background must be as low as possible to reduce noise in detection during 
the synthesis; and adsorption of the fluorescently labeled substrates must be low to help keep 
noise at a minimum. Passivation of mixed material nanostructures is an area of intensive active 
research, but the most common materials are gold-on-glass based structures. 35, 36 Aluminum-on-
glass structures have many advantages over gold when optical confinement of the ZMWs is 
considered as it has better reflectivity and a shorter optical skin depth. Aluminum, however, is 
corrosive in aqueous medium.37 Organophophorus acids have been shown to react with metal 
oxides, such as aluminum oxide, while not interacting with silicon dioxide surfaces in aqueous 
medium, offering a method of protecting the aluminum while leaving the glass of the structure 
unadultered. 38,39 
To selectively passivate the aluminum from protein absorption, polyvinylphosphonic acid 
(PVPA) is thermally deposited from a 2% aqueous solution of PVPA by incubation at 90°C for 2 
minutes and then annealed in a dry oven at 80°C for 10 minutes.40 To test the bias of these 
passivated aluminum surfaces on glass, adsorption of neutravidin as a test protein was conducted 
on both PVPA treated and untreated aluminum-on-glass nanostructures and the protein 
fluoresced for visualization with fluorescence microscopy. As shown in figure IV.4, the treated 
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aluminum showed tremendous bias with respect to physisorbtion of neutravidin. Untreated chips 
show bright aluminum squares as reflections from the metal intensify fluorescence, while treated 
chips show dark aluminum squares where little physisorbtion is found.41 
When treated with phi29 polymerase, similar protein physisorbtion bias was found. A 
localization density ratio of over 400:1 on glass over aluminum was conferred, demonstrating the 
suitable passivation of the aluminum on the ZMW nanostructures for DNA synthesis .42  
 Preparing the ZMW for immobilization of the polymerase on the glass of the waveguides 
is further enhanced by the use of an additional biotinylated polyethylene glycol layer. The 
biotinylated polyethylene glycol (PEG) polymer is deposited on the silicon dioxide by a process 
known as silanization. Using Biotin-polyethyleneglycol-trimethoxysilane, the glass bottoms of 
Figure IV.4  PVPA treated (bottom) verses untreated (top) whole aluminum-on-glass chips (left; scale bar, 1 mm) and 
aluminum glass interfaces (right; scale bar 10 µm) with deposited fluorescently tagged neutravidin. Reproduced from 
J. Korlach (2007). 
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the ZMWs are effectively covered in Biotin using the PEG polymers, known commonly as 
PEGylation, by a reaction between the trimethoxysilane and the silicon dioxide. 43  The now 
biotinylated ZMWs are treated with streptavidin at 22°C for ten minutes at a 2-fold streptavidin 
to polymerase molar excess.  
 Biotinylation is a process by which the coenzyme biotin—also known as vitamin B7 or 
coenzyme R, molecular formula C10H16N2O3S, see figure IV.5—is covalently attached to 
another biomolecule. This technique has been used extensively in laboratory research and 
biomolecule preparation for decades because biotin and the avidin type proteins bind with an 
incredible degree of affinity.44 The dissociation constant for biotin from avidin is ~10-15M 
making it one of the strongest known non-covalent interactions.45  
 
Figure IV.5  Biotin 
 
Because streptavidin is a tetrameric protein which binds biotin stoichiometrically, the 
protein behaves like a glue between the biotinylated glass and the biotinylated phi29 polymerase. 
The ZMWs are washed with buffer to remove excess unbound streptavidin, followed by 
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immobilization of the polymerase-template complex at 4°C for 15 minutes by binding 
polymerase to streptavidin. Unbound complexes are washed away with reaction buffer.46  
Immobilization in this manner—using biotinylation—gives orientation consistency to the 
polymerases present in the ZMWs. This is extremely important for high-throughput sequencing. 
Randomly distributing the polymerase molecules across the ZMWs leads to a Poisson 
distribution of occupancy, and optimal loading gives only 36.8% of ZMWs with single molecule 
occupancy.47 Clearly, waveguides with no polymerases will not produce reads, but also, 
waveguides with two or more polymerases will give reads in which the sequences of the two 
polymerases cannot be distinguished and throughput is affected. Orientation, however, is not 
directed by random distribution and misaligned polymerases will not function correctly and 
throughput could be highly reduced. By utilizing biotinylation binding in the bottom of the 
ZMWs, Korlach, Turner and colleagues found that 82% of singly occupied ZMWs produced 
full-length sequence-by-synthesis reads, greatly improving the throughput of the SMRT 
sequencing system.48 
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IV.6  Phospholinked Fluorescent Nucleotides 
 
 By labeling nucleotide bases at the terminal phosphate, see Figure IV.6 below, several 
issues of processivity in fluorescence based sequencing are addressed. Because natural 
polymerase activity cleaves the alpha-beta phosphoryl bond in the phosphonucelotide, the 
nucleotide incorporated into the growing product strand is a completely unaltered deoxyribose 
nucleic acid, and the strand grows as normal, as steric hindrance is eliminated. Furthermore, it 
has been shown that extending the triphosphate moiety to four and five phosphates increased 
incorporation efficiencies.49 In several kinetic studies, Korlach and associates have shown that 
phi29 polymerase can, when all four dNTPs have been replaced with phospho-linked 
nucleotides, perform processively over thousands of bases at kinetics reaching levels of those 
associated with unmodified dNTPs—see figure IV.7. In addition, the synthesis of these special 
nucleotides has been elaborated in the literature—the procedure is detailed in Appendix D.50  
Figure IV.6  Penta-phosphate-linked Alexa Fluor 488 
aminohexyl-O-dG5P 
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IV.7  Polymerization Rate Comparison 
 
With the primed template DNA bound to the phi29 polymerase and this complex bound 
to the biotinylated glass bottom of the ZMWs, the sequencing by synthesis reaction is ready to 
proceed. First, an enzymatic oxygen scavenging system, using protocatechuate dioxygenase, is 
added to the array. Fluorophores are very susceptible to oxidative damage, and it has been shown 
that dioxygenases added to fluorescence based single-molecule experiments greatly increase the 
life of the fluorophores.51 Finally, the four phospho-labeled deoxyribose pentaphosphate nucleic 
acids are added to the array along with manganese acetate to concentrations of 250 nM (each 
nucleotide) and 0.5 mM respectively and the polymerization initiates at 30°C for the length of 
time needed for suitable sequence coverage.  
Rates of polymerization of the phi29 polymerase 
utilizing phospho-linked nucleotides exhibit classic 
Michaelis-Menten saturation kinetics. Consistent with 
Michaelis-Menten kinetics, maximum saturation velocities, 
Vmax, and substrate concentration at half-maximum velocity, 
K1/2, values can be calculated for any fluorophore/nucleotide 
combination and a kinetic fingerprint equation developed 
for predicting polymerization velocities, Vel, as a 
function of nucleotide concentration, C.52  
Figure IV.7 DNA products after 5 minute extension 
reactions. Native dNTPs are compared to phospho-
linked dN5Ps and conditions with just one base-linked 
dNTP alongside a negative control. 
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The elongation velocity is given by: 
   =     ∙     +   
 
Equation IV.1 
To optimize the read accuracy, nucleotide concentrations have to be carefully tuned to 
optical read capabilities. Background fluorescent noise is somewhat concentration dependent, 
however, the use of the ZMWs provides a wide window of concentrations which provide 
acceptable signal to noise ratios. The small detection volume surrounded by reflective aluminum 
limits penetrative light to no further than a few nanometers into the waveguide and additionally 
limits diffusion-mediated fluorescent occupancies to the order of 2-10 µs verses nucleotide 
incorporation events on the order of milliseconds, providing easily distinguishable pulses. Base 
discrimination and read confidence are based on pulse and inter-pulse durations (see 
fluorescence discussion below). Nucleotide concentrations of 250nM each provide an average 
polymerization rate of 4.7 ± 1.7 bases/second with an acceptable error rate and signal to noise 
ratio.53  
IV.8  Dissociation of Synthesized Strands and Re-Complexing with 
New Primed Template Strands 
 
 
 After a polymerase has completed synthesis of a complementary strand from a primed 
template strand, the newly synthesized double strand dissociates from the enzyme and the 
enzyme is left free to re-associate with another primed template and continue sequencing. The 
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re-complexing of a new primed template is a diffusion-mediated event. Because the binding of 
primed DNA templates to polymerases is quite an exergonic reaction,54 we assumed that any 
primed-template DNA which made its way to the bottom of a waveguide containing an empty 
polymerase would bind and proceed with synthesis. 
 To calculate the rate at which primed-template DNA enter the waveguides, Fick’s law of 
diffusion was applied to free DNA molecules in solution. Fick’s law of diffusion has the form: 
 
 
Equation IV.2 
Where, J is the flux (in        ∙        ); D is the diffusion coefficient of the DNA (in      ); and      is 
the special derivative of the concentration gradient.  
 Robertson et al. have developed a correlation between DNA length and its diffusion 
coefficient of the form: D = 2.3453 ∙ (     ℎ      )  .    .55 This correlation gives our 
average two kilobase DNA fragments diffusion coefficients of 2.488       . This value is fixed for 
our fragment length at reaction temperature. 
 The concentration gradient, however, is manipulatable, and it must be. In order for our 
fragments to be distinguished from one another, there must be some distinguishable signal to the 
recording computers that an old fragment is done being sequenced and a new one has started, or 
reassembly will be unnecessarily more complicated. In this regard, we calculated the rates of 
diffusion into the ZMWs for various concentration gradients. At a low limit of 0.1 ng per 50 µl 
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(a lower limit based on a hypothetical failed genomic amplification using minimal genomic 
template, which correlates to a molarity of 1.62 picomolar) the flux is shown to be: 
 =2.488         ∙   .   ×           .     ∙     =   .   ×              ∙    
 
 
Equation IV.3 
At the high limit of 40µg per 50µl (based on undiluted amplified genomic product, 
corresponding to a molarity of 0.647 micromolar) the flux is found to be: 
 =2.488        ∙   .   ×          .     ∙     =   .   ×              ∙    
 
 
Equation IV.4 
When these fluxes are multiplied by the area of the waveguides (100nm in diameter yields well 
areas of 7854 nm2) and Avogadro’s number (6.02 x 1023 strands of DNA per mol) the diffusion 
rate into the waveguides of the DNA strands is found: 
    Lower Limit Upper Limit 
Diffusion Rate (strands/s)   0.00019 76.11 
Dissociation/Recomplex Lag  5,256 s 0.013 s 
 
Table IV.1 Diffusion rates calculated from correlated DNA diffusion coefficients and the consequential 
lag times between dissociation of completed complementary synthesized strands and reassociation 
with new primed-template DNA strands, at reasonable limits of operation. 
 
Clearly, at the lower limit, throughput would be highly compromised, as on average, hours 
would be spent waiting for free polymerases to bind new template strands. The higher limit 
presents another problem, however, as lag time between fragments would be on the order of 
inter-pulse widths, meaning that no distinction between the last base of a fragment completing 
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synthesis and the first base of a fragment starting synthesis could be made, and the fragments 
could not be separated, causing sever reassembly problems. In order to optimize distinction 
between fragments yet reduce impact on throughput, DNA template concentration is chosen 
where the lag time between fragments is just longer than 75% of inter-pulse durations, such that 
the majority of fragments are distinguished, yet throughput is not significantly affected. Using 
data collected from Eid et al., a cumulative exponential distribution was evaluated to find that 
three-quarters of inter-pulse durations would be less than one second long. To then find the DNA 
concentration at which mean lag time between dissociation and re-complexing events was longer 
than one second, the flux has to be calculated and then the DNA concentration backed-out using 
Fick’s Law: 
1       1        ∙  1   6.02 × 10           ∙  10.007854    =          2.115 ×  10           ∙     
 
 
Equation IV.5 
 
 
2.115 ×  10           ∙      ∙  0.1    ∙     2.488    ∙ 10     1       =                  8.5   
 
 
Equation IV.6 
With an optimized DNA concentration of 8.5 nanomolar calculated, the final reactants can be 
added and the reaction begun. 
IV.9  Error Rates and Possible Sources of Error 
  
 
 Errors are currently on the order of 0.214%. Of these errors, the majority (44%) are 
deletions. Deletions occur from incorporation events which are too short, or when inter-pulse 
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durations are too short to be confidently detected. Nucleotides with no fluorescent label—so 
called ‘dark nucleotides—can be sources of deletion errors however, HPLC analysis show that 
the phospho-linked nucleotide composition is over 99.5% pure,56 and kinetic studies have shown 
that phi29 polymerase shows no discrimination between phospho-linked and native 
nucleotides.57 Additionally, statistical models predicting pulse-width distributions and projected 
probabilities of pulse detection show excellent consensus with the deletion rates observed. Future 
research and development efforts will focus on reducing these errors by further modifying the 
enzyme to reduce the fraction of short incorporation events as well as increasing camera frame-
rate to strengthen the resolution of inter-pulse widths.58 
 Insertion errors are caused mostly by dissociation of cognate nucleotides from the 
enzyme before the formation of the phosphodiester bond to the growing complementary strand 
resulting in duplications. As with deletions, these errors can be addressed by modifying the 
enzyme to reduce the free-energy of the nucleotide substrate in the active site thereby reducing 
the dissociation constant for cognate nucleotides. Mismatches were accountable to spectral 
misassignments between fluorophores with close emission wavelengths. These errors can 
addressed in future experiments by using dyes with more separation between emission 
wavelengths, as well as increasing the camera sensitivity.59   
 
 
 
 
 
D N A  P o l y m e r i z a t i o n  
 
 
54 
 
IV.10  Conclusions 
  
 
 With a waveguide of 512 by 512 ZMWs with 1 micron square pitch spacing, an area of 
0.318 mm2 makes up the reaction vessel interface. With a liberal 1mm tall aqueous reaction 
mixture added, our reaction volume comes to 0.318 mm3 or 0.318 µl. Once our template-
complexed polymerase has been immobilized on our nanostrucure the reaction mixture is added 
which is comprised of the following, in molar amounts shown, and the sequencing reaction 
proceeds at 30°C:  
 
Compound   Concentration Comments 
DNA  8.5 nM 
Template fragments of which are replicated 
forming sequencing output 
Primers  50 µM 
Random hexamers prime template strands for 
sequencing by synthesis 
dN5Ps  250 nM (each) 
Substrate for nucleotide addition to growing 
complementary strands 
ACES  50 mM 
pH buffer for biochemical reactions in the 
range 6.1-7.5 
Potassium Acetate  70 mM Salt buffer 
Dithiothreitol  5 mM 
Reducing reagent which deprotects thiolated 
DNA for efficient processivity of polymerases 
Manganese Acetate  0.5 mM 
Metal cation necessary for function of many 
DNA polymerases 
 
Table IV.2  Combined at 30°C, these components initiate the reaction and sequences are read at the rates 
described above.
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V.  Optical Detection  
        of Single Molecules 
 
Several techniques exist for the focused analysis of single molecules. While varying 
slightly in execution, these all derive their resolving power from the minimization of one of two 
system parameters: background fluorescence, and observation volume. Either approach has a 
similar effect, namely, to reduce the probability of detecting a signal from more than one 
fluorescently labeled molecule at any given moment, enabling confident distinction between true 
signal and background noise.   
The following chapter takes a closer look at the optical system required to meet the high 
throughput required for success.  An analysis of the microscopic systems and the EMCCD 
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cameras required is performed to make sure that the setup is feasible.  A key design element of 
the optical system, the use of two cameras to view the sample, is thoroughly examined, as it is 
critical in increasing throughput.  The remainder of the chapter looks at the capabilities of those 
cameras used to determine whether or not they meet the detection requirements for successful 
observation of the sample volume.   
V.1  Confocal Fluorescence Microscopy 
 
One of the most widespread methods in practice today, due to its effectiveness and 
relative simplicity, is confocal microscopy14. As illustrated by Figure V.1, a laser beam is 
brought to its diffraction limited focus within a particular probe volume using a high-aperture 
objective lens. A pinhole (typically 50-100 μm in diameter) can also be placed at the interface 
with the sample, rejecting any light this remains out of focus. In conjunction with diffractive 
manipulation of the beam, this allows for approximately 
cylindrical observation volumes of 0.5-1.0 fl (~0.5 μm in 
diameter and ~1.0 μm in height). 
As labeled molecules enter the detection volume, the 
red-shifted photons emitted by the excited fluorophores are 
focused through the same pinhole and objective lens before 
being reflected by a dichroic mirror into the detection 
apparatus. Here the beam is divided equally between two Figure V.1 A typical confocal 
microscopy setup, adapted from 
Lundquist (2008). 
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avalanche photodiodes by a beam splitter. If multiple emissions wavelengths are present, 
dichroic mirrors can be utilize for color isolation. Alternatively, individual wavelengths within 
the beam can be separated by prisms and focused onto characteristic regions of a charge-coupled 
device (CCD) detector. In this setup, both the intensity and position of the light would be 
recorded, allowing simple differentiation among many distinct fluorophores.  
V.2  High-Multiplex Confocal Microscopy 
 
For applications like SMRT sequencing that require spatial multiplexing, scanning 
confocal microscopy has been the standard measurement technique. This method is proven and 
well understood, but the frame rate is limited by the period of the scanning mechanism and by 
design, it cannot provide continuous observation of any single site. Our throughput requirements, 
however, demand the simultaneous monitoring of over 250,000 individual waveguides, 
completely ruling out scanning microscopy as a viable detection method. Rather, we will make 
use of recent advances in high-multiplex confocal microscopy to facilitate the collection of real-
time, high-sensitivity fluorescence data60. 
The greatest single innovation in this field is the use of holographic phase masks (HPMs) 
to split a single excitation laser beam into an array of sub-beams at the same wavelength. These 
HPMs can be customized to generate almost any pattern of excitation radiation and almost any 
wavelength, and are thus readily adaptable to any number of sample volume configurations.  
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In consideration of the multiple excitation 
wavelengths required by the four fluorophores in 
use, multiple arrays from different sources could 
be combined using relay lenses and dichroic 
mirrors into a common illumination plane before 
being directed by the objective lens onto the 
sample. The emitted light is then collected through 
the same objective, deflected 90 degrees, split, and 
focused onto two single photon sensitive EMCCD 
chips. Previous applications of this CCD-based 
technique have utilized prism assemblies to disperse the emitted light over several CCD pixels, 
providing continuous color separation for the spatial identification of wavelength. 
In order to obtain high-resolution spectra, however, 15 pixels would be required for each 
ZMW, severely limiting the observational capacity of each EMCCD. Moreover, the entire 
purpose of a ZMW is to attenuate background noise by reducing observation volume. This 
renders confocal techniques, even those which support simultaneous spatial multiplexing, 
unnecessarily complex and expensive.  
V.3  Two-Color Wide Field Microscopy 
 
Our detection process will utilize some of the simplest illumination and observation 
methods, relying almost entirely on the properties of the ZMW and the back-illuminated 
Figure V.2 High-multiplex confocal microscopy 
setup. The images in the bottom right illustrate 
the spatial wavelength identification method. 
Reproduced from Lundquist (2008). 
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EMCCD to facilitate high-quality signal acquisition. Excitation energy will not be provided by 
laser, but by a mercury arc lamp whose output will be split, wavelength filtered, then recombined 
onto the ZMW array. This requires no complicated optics, such as phase masks, while still 
providing uniform illumination. A high numerical aperture, low-distortion objective will enable 
the observation of the entire ZMW array simultaneously with the precision necessary to map 
each waveguide to a single EMCCD pixel. The EMCCDs themselves are mounted in a manual 
precision dual-port camera adapter for reliable CCD-to-chip alignment.  
The fluorophore detection technique has also been designed to be optically simple and 
equipment efficient. Rather than devoting 15 pixels to each ZMW for spatial identification, we 
devote only two. Proper identification is performed by recording separate wavelength spectra on 
each pixel, and taking the ratio of intensities between the two. Physically, this is accomplished 
by using a dichroic mirror in the beam splitter at the core of the precision alignment adapter. 
Wavelengths higher than the cutoff are reflected to one camera, while the rest pass through to the 
second. Since both CCDs are aligned to the same waveguide array with 1-to-1 mapping, each 
pair of pixels will correspond to a single ZMW, and record the progress of a single polymerase 
molecule. The ratio of emissions intensities detected on each CCD will determine which 
fluorophore was excited, thereby identifying the nucleotide just added to the sequence. Despite 
doubling the number of cameras required, this method yields a 15-fold reduction in the number 
of pixels needed to identify a fluorophores, thereby reducing the overall detection equipment 
requirements 7.5-fold. 
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In order to guarantee that the individual peaks corresponding to the presence of a specific 
fluorophore, and thus a specific base, could be detected using the dual camera system, a read 
error analysis was performed using the Monte Carlo statistical method on the specific 
fluorophore peaks.  Monte Carlo measures the independent fluctuation of multiple variables that 
affect a function.   This is a perfect statistical method for analyzing the variation of light intensity 
read by both cameras.  
 As described earlier, the method used to determine the identity of the fluorophore 
emitting the light involves comparing the intensities hitting each camera.  Since each fluorescent 
molecule has an individual light intensity distribution over a range of wavelengths, creating a 
cutoff wavelength for each camera divides the intensity readings between two cameras.  With the 
individuality of each intensity distribution in mind, then the ratio of intensities for each peak 
Figure V.3  Intensity Distribution of Four Fluorophores. The figure shows the intensity distributions over 
a range of wavelengths for fluorophores coupled with (1) dATP, (2) dTTP, (3) dGTP, and (4) dCTP.  The 
camera wavelength ranges split the peaks at 638 nm, with camera 1 capturing the majority of dATP and 
dTTP, and camera 2 capturing the majority of the dCTP and dGTP intensities.   
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should be molecule specific.  That is Rpeak for each fluorescently tagged dNTP should be specific 
so that identification of each base is possible.  Rpeak is given by: 
     =         Equation V.1 
where Ic2 is the intensity reading for camera 2 and Ic1 is the intensity reading for camera 2.  Using 
the intensity distributions in Figure V.3, the areas under each peak can be found.  The 
wavelength cutoff between camera 1 and camera 2 was chosen to be at 638nm wavelength, at the 
intersection of the intensity distributions for peaks 2 and 3.  This allows for relatively balanced 
intensity readings for each camera.  Using ImageJ software, the area under the intensity curve for 
each peak is measured over the wavelength ranges for each camera, giving Ic1 and Ic2 readings.  
Figure V.4  Intensity Division of dTTP Fluorophore for Cameras 1 and 2. The figure above shows the normalized 
peak for the dTTP attached fluorophore.  The line down the middle represents the wavelength cutoff for 
cameras 1 and 2, with camera 1 on the left and camera 2 on the right.  The area under the peak is measured for 
the wavelength coverage of each camera using ImageJ software.  The same process was repeated for the other 
three fluorophores. 
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Using these values, the ratio of intensity readings of camera 1 vs. camera 2 can be calculated.  
For example, Ic1 and Ic2 for dTTP were found to be 28178 and 1801, respectively, giving an 
intensity ratio of Rpeak=0.063915.   
     = 1801 28178 = 0.0639145
 
Equation V.2 
In order to estimate the deviation from this value, a Monte Carlo statistical analysis was 
performed using MATLAB.  The Monte Carlo method requires knowledge of the standard 
deviation of the peak intensities captured by each camera.  This is a difficult proposition, since 
Invitrogen does not provide data on the variation of the intensity vs. wavelength variation for 
their Alexa-Fluor dyes.  An alternative method for finding the standard deviation is possible 
using brightness deviation values (See Table V.1)20.  Since brightness correlates with light 
intensity, we assume that the standard deviation for the brightness also directly correlates with 
the standard deviation for each peak area of the normalized intensity curves.  Therefore it is 
possible to find the standard deviation percentage for each fluorophore peak.   
                  % =     ℎ         ℎ         .          
 
Equation V.3 
 
                  %    = 39 2781 × 100 = 1.4024%
 
Equation V.4 
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As shown above, the standard deviation percentage for the dTTP intensity is 1.4024%.   
By multiplying the standard deviation percentage by the Ici values, a standard deviation for the 
intensity readings of each fluorophore for each camera can be estimated.   
       1    .       =    .   . % ×    = 395.1607
 
Equation V.5 
The standard deviation readings for each peak and for each camera are shown in Table 
V.1 below.  These standard deviations can then be used to carry out a Monte Carlo simulation 
using MATLAB.  The simulation examines the distribution of Rpeak using Equation V.1 and the 
standard deviations found for Ic1 and Ic2.   The normal distributions for Ic1 and Ic2 are first 
generated in MATLAB using the following code: 
ca_cb= (randn(n,1)*std)+mean; 
 
where std is the standard deviation of the intensities found earlier, n is the number of iterations, 
and mean is the average value of the intensity per camera, or in this case Ici.  This process is 
performed for the intensity distribution of each peak for every camera.  The Monte Carlo 
simulation is carried out using the distribution generated for each camera for a specific peak. 
peak2 = c2_2./c1_2; 
 
where the above code is analogous to Equation V.1 for the dTTP intensity distribution.  The 
process is repeated for dATP, dGTP, and dCTP.  Once the distribution of each peak ratio is 
generated, the next step is to calculate the medians and the standard distributions found for each 
fluorophore.  These are listed in Table V.1 on the previous page.  By plotting the histograms of 
each fluorophore camera intensity ratio, it is evident that there is no overlap between the ratios 
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for each fluorophore peak.  It is clear that by using the dual camera peak identification setup 
would not produce base mismatches due to overlap of Rpeak  values.    The  complete MATLAB 
code for the simulation is found in Appendix E.6.   
 
 
 
 
 
 
  dATP dTTP dGTP dCTP 
Peak  1 2 3 4 
Brightness  6,446 2,781 4,865 2,691 
Brightness Std. Dev.  109 39 92 41 
Brightness Rel Std Dev (%)  0.01691 0.014024 0.018911 0.015236 
Ic1  24,198 18,178 548 110 
Cam 1 Std. Dev.  409.181 385.160 10.363 1.675 
Ic2  226 1,801 25,175 31,303 
Cam 2 Std. Dev.  3.822 25.257 476.074 476.932 
Rpeak  0.0093 0.0639 45.9398 284.5727 
Ratio Std. Dev.  6.36 x 10
-5 3.65 x 10-4 0.352 1.76 
Table V.1  Data for Dual Camera Error Analysis. The following table shows data required for performing a 
Monte Carlo simulation demonstrating that the reliability of using a two camera system in order to detect 4 
different fluorescent molecules.  Ic1, and Ic2, are values obtained using ImageJ for the areas underneath the 
intensity distribution curves from Fig. IV.3.  The areas are measured for the intensities for the wavelength 
range of each camera, set at 638 nm.  The Camera standard deviation columns are obtained by  multiplying 
the Standard deviation % column with the Ic1 and Ic2 columns.  The Ratio Standard Deviation column is the 
standard deviation calculated using a Monte Carlo simulation in MATLAB.   
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Figure V.5  The above image shows histograms produced for the distribution of log(Rpeak)values for dATP, dTTP, dGTP, 
and dCTP using the Monte Carlo method in MATLAB.  The red, green, blue, and magenta curves are the histograms for 
dATP, dTTP, dGTP, and  dCTP, respectively.  It is clear that the lack of overlap between each Rpeak value demonstrates 
that the two camera system should not result in base mismatches due to Rpeak value overlap. 
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V.4  Fluorescence Detection and Signal to Noise 
 
Electron Multiplying Charge Coupled Devices (EMCCDs) present a critical component 
in the design for high throughput genome sequencing.  EMCCDs are capable of capturing single 
photon events at high read-out speeds.  The chip uses the principles of impact ionization in order 
to register and multiply the presence of an electron.  In order to deal with issues of background 
noise, EMCCDs employ an Electron Multiplying (EM) solid state register that amplify the signal 
from the electrons before passing through the output amplifier.  The extra register at the end of 
the first register allows for the amplification of the signal without requiring an image intensifier, 
which would add noise to the image, lowering the camera performance.  This elimination of 
background noise is critical when dealing with light signals from an individual molecule.  This 
design is perfect for use in conjunction with the waveguide containing the biochemical 
reaction.61   
The light emitted from each waveguide is lined up 
with the individual EMCCD pixels using a mechanical stage.  
The EMCCD desired for the setup is the iXon+ DU-897E 
from Andor.  The camera provides a 512x512 resolution chip 
with individual pixels that are 16µm in size.  This dedicates a 
single pixel to manage the light from an individual 
waveguide.62   
Figure V.6 Andor iXon+ DU-897 
EMCCD Camera (Andor Tech. 
PLC, Belfast, Northern Ireland) 
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An important aspect to photodetection is the quantum efficiency (QE) of the CCD.  The 
QE is defined as the percentage of photons that are actually detected and then transmitted as 
electrons by the photodetector.  The QE of a camera is important in determining the signal to 
noise when detecting the light used.  In general the higher that the QE of the camera being used 
is, the better the better the quality of the reading will be.  
One of the most important determinants of the QE of an 
EMCCD is the wavelength of the light that is detected.   
For the purpose of the sequencing process, wavelengths 
between the range of 500nm and 700nm need to be 
detected by the EMCCD.  According to the QE vs 
wavelength curves generated by Andor (see Figure V.7) , the iXon+ 897 ranges in QE from 0.95 
to 0.98 within the desired wavelength range.  This is as close to an ideal QE as possible with the 
current technology allows.24   
Another important quality of the EMCCD is its readout speed.  The camera should be 
able to detect the light produced from the reaction faster than the actual reaction occurs.  That is 
to say the frame rate of the camera should be significantly faster than the excitation period of an 
individual fluorophore.  This is important, since the fluorophore is excited while it is being 
attached to the DNA template.  Once the next base is added, the fluorophore is no longer 
detected and the next signal has to be dealt with.  Therefore in order to prevent base readings 
from blurring together, the frame rate of the camera should be faster than the nucleotide addition 
Figure V.7 Wavelength dependency of QE of 
the Andor iXon+ Du-897 EMCCD camera.24 
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rate for the phi 29 polymerase.  With a frame rate of 31 frames per second (See Appendix D.3) 
the iXon+ 897 easily surpasses the maximum dNTP addiction rate of 4 bps.   
In order to successfully identify the presence of a fluorescent molecule, it is important to 
have a favorable signal to noise ratio.  Signal to noise ratio simply describes the relevant signal 
from the fluorophore as compared to the extraneous information.  This extraneous information 
can be due to several different factors, including background noise and shot noise.  Background 
noise includes any signal coming from ambient sources.  Shot noise occurs due to statistical 
fluctuations of finite number of particles detected as a result of random arrival time.  The number 
of photons collected by the detector can be described as a Poisson distribution and the noise can 
be described as the standard deviation of that or the square root of the average number of 
photons collected.  Therefore, a simplified version of the signal to noise ratio can be modeled by: 
   =      =      Equation V.1 
where np is the average number of photons detected.20  From this equation, it is easy to see that 
as the number of photons detected increase, the signal to noise ratio increases.   When accounting 
for noise from the signal transmission in the light detector and for the baseline noise read or the 
background read, the relationship becomes: 
 
 
   =    2   −      
 
Equation V.2 
O p t i c a l  D e t e c t i o n  
 
 
69 
 
where bkg is the background noise, and √2 is a correction for the noise from the EMCCD 
camera.20  Considering all of these conditions, a signal to noise ratio near 100 would be favorable 
for a reliable read.  Using these parameters, Eid and colleagues tested a waveguide containing 
phi29 polymerase and fluorophore labeled dNTPs.  The lowest signal to noise ratio found was 
356 for the dTTP fluorophore.  This number is well above the desired ratio of 100, meaning that 
using the same fluorophores, the light signal can be reliably detected.  The experiment also 
proved that a large number of photons are emitted by the fluorophores, on the order of 250000, 
making the background noise inconsequential.20     
In order to account for the potential difference in EMCCD cameras used in the 
experiment, one can consider the quantum efficiency (QE) of the camera.   
   =   ∙      ∙   +      Equation V.3 
where nn refers to the sensor noise.63  Since, np is so high, the sensor noise is not as important, it 
can be ignored.  Using the QE of around 0.98 for the camera in our experiment 
   = 0.99        Equation V.4 
which for a large number of photons emitted by the fluorophores gives a favorable signal to 
noise ratio estimation.24   
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V.5  Conclusions  By using two iXon+897 EMCCD cameras along with a high-multiplex confocal microscopy setup per station, the high throughput imaging necessary to view the throughput of the biochemical reaction on the chip is possible.  After analysis of the dual camera setup, it is clear that it is possible to view and differentiate the four fluorophores in the ZMW by dedicating a total of two pixels per waveguide, maximizing the throughput of the setup.  Upon considering the signal to noise conditions from the setup, the use of iXon+897 EMCCD in conjunction with the fluorophores used to tag the DNA, the high signal to noise ratio proves to be favorable for quality performance viewing of the reaction taking place, and a subsequently lower error rate in reading the DNA sequence.    
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VI.    Genome Assembly 
 
 The field of bioinformatics encompasses the development of databases, algorithms, and 
other computational techniques for the indexing and analysis of biological information, including 
DNA sequences.64 This unique discipline lies at the intersection of computer science, biology, 
mathematics, and medicine, providing the very tools required to compile and analyze genomic 
data. The functionality provided is similarly diverse, ranging from protein modeling to gene 
mapping, and even to determining the evolutionary history of a particular organism. Indeed, 
without these advanced capabilities, a full-genome sequence would be of little practical value, as 
its relevant information content could not be decoded.  
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 This chapter, however, will focus exclusively on the aspect of bioinformatics that is most 
relevant to PennBio’s business plan – genome assembly. With a sample of some 27 million 
fragments of random length and sequence being generated during the observation of the SMRT 
chip, this final step in genome “production” is perhaps the most difficult and resource-intensive. 
Many different assembly techniques exist, all varying in experimental fragment length, 
knowledge of the target sequence, and specific alignment algorithms.  
The following discussion of the Human Genome Project and Celera Genomics illustrates 
quite clearly the rapid, almost quantum advances that have been made in genome reassembly in 
the last two decades, and provide important background and precedent for the PennBio method. 
Further detail will then be given regarding the specific considerations and calculations that were 
involved in the development of a reliable, efficient assembly procedure. Finally, the results of an 
original Monte Carlo assembly simulation will be discussed with respect to its usefulness as a 
model validation tool, and as a means of predicting the computational resources necessary to 
meet PennBio’s throughput goals. 
VI.1  The Human Genome Project 
 
 The early whole-genome sequencing ventures, including the Human Genome Project 
(HGP, 1990-2003), took what is now considered a brute force approach to sequencing 
determination65. The complete human genome was fragmented into long strings, some 150 kbp 
in length, and distributed to laboratories around the world for analysis. These genome fragments 
were sequenced in a processive manner, starting at one end and proceeding to the other, one base 
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position at a time, before the completed fragments were mapped to chromosomes and 
reassembled into a single consensus genome. This method is referred to as the “hierarchical 
shotgun” approach, and was selected by the HGP principally for its ability to accurately map 
repeat-rich sequences, and also because it allowed the project workload to be shared across 
several analysis sites. In the Nature article announcing the endeavor’s completion, the authors 
insist that “the advantages of this more conservative approach outweighed the additional cost, if 
any.”66  
 During its thirteen year timeframe, the HGP was the focus of over 20 public molecular 
biology laboratories and approximately $3 billion is public funding. Its contributions to genetic 
science, particularly as an ardent proponent of the human genome as public-domain information, 
are indisputable, but many have questioned the efficiency of their sequencing method. In fact, 
just eight years into the Project, a private biotechnology firm – Celera Genomics – launched a 
parallel human genome sequencing venture based on the whole-genome shotgun (WGS) 
technique. 
VI.2  Whole-Genome Shotgun Sequencing 
 
 Whole-genome shotgun sequencing is distinguished from the hierarchical method by its 
short read lengths. In contrast to the 150 kbp fragments used by the publicly-funded effort, 
Celera generated fragments a mere 550 bp in length67. The entire fragment library was then 
aligned simultaneously to create a full consensus genome, rather than first producing long 
intermediate sequences. By 2001, Celera had caught up to the public HGP, and the two 
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Figure VI.1  A graphical comparison of the hierarchical (left) and whole-genome 
shotgun (right) sequencing methods. Reproduced from Mihai (2004). 
competitors published their draft genomes within two months of each other. The price of 
Celera’s finalized sequence, however, was reported to be $300 million – a tenth of the public 
funding required. As striking as this cost differential is, it must be considered in context. Celera’s 
project had, on its first day, free and unrestricted access to the public project’s progress, which 
was updated daily. The extant sequence information made the mapping of short fragments much 
less uncertain than the initial de novo assembly case, and permitted the use of less rigorous 
assembly techniques68. It is difficult to say whether the approach would have been as successful 
without a template, incomplete though it was. Indeed, the scientists on the public side may have 
been right to choose the more painstakingly accurate method. 
 But regardless of what could have been, Celera’s success confirmed that WGS 
sequencing was a viable and time-efficient alternative to the older techniques. Modern 
sequencing operations are nearly unanimous in their acceptance of this approach, and it has 
benefitted considerably from advances in computing power and assembly algorithms. 
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VI.3  The PennBio Strategy 
 
 PennBio’s reassembly strategy combines the sensitivity of WGS with the public-domain 
human genome sequence in a process often called comparative genome assembly65. As in the 
classic technique, customer genomes are randomly fragmented into 2000 bp lengths, but rather 
than being aligned to each other to produce a consensus sequence, each fragment is mapped to 
the available genome. Given that individual sequences differ by one base in everything thousand, 
on average, and the polymerase-related error rate is extraordinarily low modern alignment 
algorithms can execute the mapping with a success rate of nearly 100%, and in a fraction of the 
time and computational complexity required by de novo assembly46.  
 In this way, PennBio provides its customers with the most sophisticated of modern 
analysis technique, resting on the shoulders of nearly two decades of human genomic study. 
Exceptional accuracy, not only in identifying known SNPs, but at every base position is what 
makes each sequence an essential tool in the most advanced molecular diagnosis both today, and 
in the future as our medical understanding of the genome continues to grow. At the same time, 
low cost and unprecedented throughput for bring this indispensible resource to the average 
customer for the first time. 
VI.4  The Coverage Problem 
 
 The most significant shortcoming of the shotgun method is its dependence on an 
overgeneration of information, i.e., the requirement that the total length sequenced is several 
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times longer than the target genome, itself69. With no such redundancy, the random nature of the 
synthesis reaction would certainly yield gaps in the final genome. But as the total length 
sequenced increases, the probability of missing any particular base position decreases. The 
relationship follows a binomial distribution: 
Pr( ) (1 )k n k
n
K k p p
k
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Equation VI.1 
where K is a random variable for the number of successes, k is a realization of this variable, n is 
the number of trials performed, and p is the probability of success for each trial. Since the 
number of successes is typically specified by the requirements of the reassembly algorithm, an 
alternative formulation of this distribution – the negative binomial – is more useful. This 
expresses the probability, f(n), that k successes will be achieved in n trials: 
1
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n k
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Equation VI.2 
 
Given a particular base position, a success is achieved if a sequenced fragment exists containing 
that base, under the assumption that it can be properly positioned by a reassembly routine. 
Defined more rigorously, a success is achieved if the polymerase under observation has at any 
point added a nucleotide at that particular position, generating a measureable signal, which was 
then translated into a character in a random fragment which can be accurately positioned in the 
final genome. Each of these steps in the single-position sequencing operation has a likelihood of 
failure, and contributes to the determination of p. Therefore, each of these processes underwent 
G e n o m e  A s s e m b l y  
 
 
77 
 
individual statistical modeling in order to generate a final estimate for the redundancy required 
for complete coverage. The following analysis is performed at the single base position level. 
VI.4.1  Probability that the Polymerase Reached the Base Position 
 If a certain base is to be sequenced the polymerase must, at very least, physically arrive at 
that particular position. Since polymerization is unidirectional, the probability that this 
requirement is satisfied can be divided into two sub-probabilities: that the polymerase attaches to 
the template strand before a given position, and that it does not release the template before 
reaching it. 
Phi29, and all DNA polymerases, will only bind to double stranded DNA. Since our 
templates are necessarily single-stranded, short lengths of primer ssDNA are annealed to it, 
providing the enzyme with attachment points. Template priming in this design is accomplished 
by means of random-sequence six-base fragments of ssDNA (hexamers). These are demonstrated 
to bind to the target ssDNA genome fragments randomly, and since polymerization can only 
begin where a primer is bound, the actual sequenced strings will, themselves, have a random 
distribution that is both a function of fragment length and the relative primer and target 
compositions.  
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Random primer binding is modeled by the Poisson distribution, with a rate parameter, λ, 
and a total nucleotide distance, x (often called exposure)70: 
( )( )Pr( )
!
r xx eR r
r
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= =
 
 
Equation VI.3
 
 
This equation expresses the probability of observing r primer binding events over a length of x 
bases of ssDNA. In this case, λ is defined as the molar ratio primer to template, which is 
equivalent to the ratio of the number of primer hexamers, nprimers, template fragments, nfrag: 
primers primers
genomefrag
frag
n n
ln
l
m
= =
 
 
Equation VI.4
 
where lgenome is the length of the human genome (3 gbp) and µfrag is the mean length of a 
fragment (2 kbp). Taking the genome and mean fragment lengths as constants, this parameter can 
be optimized by varying the number of primer molecules present for a given coverage 
multiplicity. 
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 Realistically, there will be a large excess of template DNA in the reaction mixture. 
Therefore, low concentrations of unprimed template are not expected to have a significant effect 
on the overall sequencing rate. It becomes more important to consider the number of primers per 
fragment, since the polymerase must pause to remove these if they are encountered during 
polymerization, causing a noticeable delay. In this case, the acceptable proportion of unprimed 
fragments was set at 10-1, yielding a rate parameter of 2.3 (equal to the mean), which represents a 
6-fold decrease in the amount of random primer required for each sequencing reaction without 
sacrificing performance. 
 
Assuming priming is optimal and the enzyme has begun to sequence its template, there is 
a probability of it detaching before polymerization is complete. This probability increases with 
total distance traveled along the template – a characteristic distance that varies greatly from 
enzyme to enzyme. Indeed, phi29 was selected in part due to its capacity for very long read 
lengths, with a reported mean value of 70 kbp. Like primer binding, the occurrence of a release is 
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Figure VI.2  The optimal priming strategy. A less aggressive approach reduces 
primer-excision lags and conserves the relatively expensive reagent (blue).  
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a Poisson event. Therefore, the distance before the first release can be modeled by the 
cumulative gamma distribution, with a mean of 70,000 and shape parameter, k, equal to 1. In this 
special case, the gamma distribution is equivalent to the exponential distribution with the rate 
parameter, λ, equal to 1/70,000: 
Pr( ) 1 xX x e l-£ = -
 
Equation VI.5 
where X is a random variable denoting the number of bases traveled, x is a realization of X, and 
Pr(X ≤ x) is the probability of a release occurring at or before x. For a mean fragment length of 
2000 bp, the probability of release at or before the terminal base was 2.8% – fairly low, even 
assuming the polymerase covered the full length of the fragment. 
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VI.4.2  Probability of Misidentifying
 While phi29 is capable of remarkabl
in an error rate of 1 in every 500 nucleotides. Like primer binding, the total number of errors per 
fragment, R, over a distance, x, is Poisson distributed with an expected rate of 
a sequenced string of 1000 bp, the mean number of errors is 9, with a 99% confidence interval of 
[0,22]. 
VI.4.3  The Complete Negative Binomial Estimate
 Given the parameters derived above, the probability of success at any particular b
position is 0.963. Unambiguous nucleotide assignment requires three successful trials per 
position (k = 3), and an incomplete coverage rate of 1 per 100,000 bases sequenced.. Evaluation 
of the distribution with these values yields a final minimum estim
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Figure VI.4 Negative binomial estimate of required coverage multiplicity. Points within the shaded 
area satisfy by the coverage and error rate specifications, and are considered acceptable.
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This multiplicity value is critical to the calculation of throughput, which in turn is central 
to PennBio’s business model. With so many random events involved in DNA sequencing, further 
validation of these estimates is certainly warranted. A Monte Carlo MATLAB program was 
developed to simulate the phi29-mediated polymerization process – allowing the manipulation of 
release rate, various error rates, and target genome length – followed by an algorithm designed to 
reassemble the sequenced fragments and assess any errors made. While the realistic genome 
generation routine is purely for purposes of model validation, the latter reassembly portion bears 
remarkable similarity to alignment software in use today, and could be used to reassemble 
personal genomes during operation.  
The purpose of this section is not to delve too deeply into the programming behind this 
simulation, but rather to illustrate the rigor PennBio’s process evaluation, and to provide 
repeatable, statistically sound evidence of the project’s practical viability. 
VI.5 Simulation Overview 
 
VI.5.1  Genome Generation, Fragmentation, and Polymerization 
 
A random genome of specified length is generated by the randseq function and stored as 
the “consensus” genome – the simulation-level equivalent of the HGP sequence. Single-
nucleotide polymorphisms (SNPs) are then inserted at exponentially distributed intervals to 
create the “actual” genome sequence of interest – the customer genome. This “actual” genome is 
sonicated into fragments of normally distributed lengths about a mean of 1000 bp, which are fed 
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to a phi29 polymerase. As it polymerizes each fragment, the enzyme introduces errors at 
exponentially distributed intervals. Deletions are also inserted to reflect possible detection faults, 
and to evaluate the robustness of the alignment algorithm to phase shifts. 
This polymerization protocol is repeated a specified number of times, randomly storing 
or deleting fragments as they are created according to the output of a uniform random number 
generator, with a probability of fragment storage of 1%. Fragment generation ceases when the 
desired coverage multiplicity is achieved, simulating the randomness with which the polymerase 
sequences the excess of DNA fragments present in the reaction mixture and allowing evaluation 
of the previous redundancy estimate. 
VI.5.2  Reassembly of Random Fragments 
 
 These fragments are then locally aligned to the “consensus” genome by the built-in 
Smith-Waterman algorithm (swalign function), recording the starting point of the alignment and 
fragment length. These data are used to keep a running tally of nucleotide “votes” at each 
position in the genome. After all fragments are aligned in this way, the votes are counted, and a 
value of A, C, T, G, or X is assigned to each position, generating the “final” genome, with X 
signifying ‘blank’ or ‘inconclusive.’ 
 A short script at the end of the program then compares the “final” genome to the “actual” 
starting genome and generates an error rate. The application of various sensitivity analysis scripts 
allows the examination of the effects of various computational and biological parameters on the 
error rate, which must be less than 1 in 100,000 bases.  
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VI.6  Initial Simulation Results 
 
 Due to memory restrictions, the initial simulations were carried out on genomes with 
lengths of less than 20.000 kbp, with 10.000 kbp being the most common length used. The final 
error rates of these first simulations were on the order of 10-3 – well above the specified 
threshold to 10-5. Many of these resulted from a failure of the alignment algorithm to correctly 
recognize deletions within the fragments, so the swalign subroutine was then modified by 
varying the penalties for opening gaps in the sequence, and the penalties for extending these 
gaps. This improved the mean error rate to 10-4, which seemed to be independent of any further 
adjustments to program parameters. 
Subsequent examination of the particular error locations revealed that they were caused 
by the concurrence of insufficient coverage (only two bases per position) and ambiguous base 
definition (a tie vote – the two bases were not identical). This was inconsistent with our 
statistical coverage predictions.  The program responded to such situations by designating that 
base ‘X’ as instructed, eventually resulting in an error in the final alignment. Two options existed 
in correcting this unanticipated deficiency – either establishing a protocol by which the HGP 
genome would resolve the ambiguity, or increasing the multiplicity. 
 Initially, the first course of action appeared more attractive, as it required little adjustment 
to the physical and temporal requirements of the sequencing system. Moreover, since the 
sequencing technique is based on knowledge of the human consensus sequences, an extremely 
accurate tie breaker was readily available. Deferring to the consensus sequence in the cases of 
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ambiguous base assignment was expected to fail if and only if the base in question was a SNP. In 
this scenario, completely random assignment would actually be more reliable, as by definition of 
“SNP,” it would not agree with the known sequence. Therefore, the expected error rate was a 
product of the SNP frequency (10-3) and the frequency of insufficient, ambiguous coverage (10-
4), which was on the order of 10-7 errors per base sequenced.  
While this seems acceptably low, and is certainly below the threshold of 10-5, it is 
nonetheless unsatisfying. First, the probability must be put into perspective, remembering that a 
human genome is approximately 3 gbp long. We would therefore expect to misidentify an 
average of 30 SNPs on each genome sequenced. Second, and perhaps even more importantly, 
SNPs are considerably more significant in the molecular diagnosis of diseases. This is why most 
sequencing technologies, until now, have relied on SNP screening – providing only the most 
effective data at a reasonable price. To allow even 30 SNPs per genome to be improperly 
analyzed would dramatically decrease our product’s diagnostic power, and could make it 
difficult to displace the SNP screening assays already in common use. 
Instead, the decision was made to increase coverage multiplicity until the average error 
rate was below 1.00 x 10-5 errors per genome. As the simulation is constructed, this was a very 
simple operation, merely requiring the manipulation of a single input constant (mult) within the 
sensitivity analysis loop. Values between 8.00 and 11.00 were examined with a step size of 0.25 
before concluding that a multiplicity of 9.00 proved the optimal balance between error rate and 
physical equipment limitations.  
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VI.7  Final Error Rate Calculations 
  
Satisfied with the program’s performance, and with the biological accuracy of the input 
parameters, the final objective of this simulation was to determine the expected error rate in each 
sequenced genome. To this end, a large sample was generated by simulation iteration. The inputs 
were fixed, and are given in Table VI.1.A. The iteration routine collected final error rates from n 
= 660 independent trials using 20.000 kbp target genomes. These were then consolidated into a 
single table of count, given in Table VI.1.B, which shows the number of trials that were 
completed with a certain number or errors. 
  
 
 
 
 
 
Table VI.1  Input parameters in the determination of error rate (A). The simulation results, as count data (B). 
 
Like many of the molecular-level processes described in previous sections, instances of 
disagreement between the final genome and the target genome were assumed to be rare and 
Poisson distributed. In order to test this hypothesis, the index of dispersion was computed for this 
data set using the formula: 
 
A. Inputs  
Parameter Value 
Genome Length  20 kbp 
Fragment Length  1 kbp 
Multiplicity  9-fold 
SNP Rate  1/1000 
Error Rate  1/500 
Deletion Rate  1/500 
B. Results 
 
Errors Per Trial Count 
0  593 
1  48 
2  14 
3  5 
4  0 
5  0 
2 0.207 1.502
0.138
D s
m
= = =
 
 
Equation VI.6 
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where σ2 is the sample variance, and µ is mean number of errors per 20.0 kbp trial. In the case of 
the Poisson distribution, the mean and variance are equal, and D = 1. When the index of 
dispersion is greater than one, the events are said to be overdispersed, and are better 
characterized by a negative binominal distribution. This adds a dispersion parameter, α, to the 
calculation, and better accounts for unobserved heterogeneity in sample. In fact, the Poisson 
distribution is simply a special case of the negative binomial with α = 0. If this can be shown to 
be the case with the sample data, a Possion approximation would be valid. 
 This possibility was evaluated by performing a negative binomial regression nbreg on the 
sample (Stata 10.2), which estimates, among other things, the dispersion parameter. For this 
sample, the reported value was α = 0.099 with a standard error of 0.067. A z-test of the 
hypothesis that α = 0, however, returned a p-value of 0.138. We therefore fail to reject the null 
hypothesis, and are justified in our use of the Poisson distribution in fitting the data. 
The maximum-likelihood estimator of the error rate is given by the formula: 
1ˆ
n
i
i
MLE
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Equation VI.7 
This is equivalent to the arithmetic mean of the number of errors, R, over n independent trials. 
The error rate for the actual sample is therefore given by: 
6
,
91 errorsˆ 6.89 10  errors/bp
(660 trials) (20,000 bp/trial)MLE avg
l -= = ´
×  
 
Equation VI.8 
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Upper (UL) and lower limits (LL) of the confidence interval can then be constructed about this 
value using the chi-square distribution72: 
2
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Equations VI.9, 10 
where R is the total number of errors observed, α is the significance level, and (20,000∙n) 
represents the sample in total bases. Several possible confidence intervals are given in Table 
VI.2, and show that that only at α = 0.0001 (99.99% CI) does the upper limit cross the 10-5 
threshold. This provides quantitative evidence that the probability of producing a genome with 
an error rate higher than 10-5 is extremely, and acceptably, low under the specified biological 
conditions. 
 
    95% CI 99% CI 99.9% CI 99.99% CI 
Lower Limit  5.55 x 10
-6 5.17 x 10-6 4.76 x 10-6 4.43 x 10-6 
Upper Limit  8.46 x 10
-6 8.98 x 10-6 9.61 x 10-6 1.02 x 10-5 
 
         Table VI.2  Confidence intervals for various values of α, centered about a mean of λavg = 6.89 x 10
-6. 
  
 
As mentioned previously, reliable SNP identification is essential if current SNP-
screening services are to be displaced by whole-genome sequencing. Indeed, if the error rate in 
the most important segments of the genome were found to exceed the 10-5 threshold, the value of 
average error rate would be meaningless. The code was therefore run for an additional n = 660 
G e n o m e  A s s e m b l y  
 
 
89 
 
iterations, this time with a new subroutine that tracked the SNP-specific error rate. The Poisson 
rate parameter was calculated, using the formula state above, to be: 
Likewise, the upper and lower limits of the confidence intervals about this mean are: 
2
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Equations VI.12, 13 
Table VI.3 shows the confidence intervals for the SNP-specific error rate, which were 
calculated using Equations VI.12 and VI.13. Unlike the average error rate, this parameter does 
not, at first, appear to be below the error threshold. The discrepancy, however, arises from the 
much smaller sample size. While the average error rate was calculated from 1.32 x 107 bp over 
660 trials, only 26,453 SNPs were recorded in twice as many (1,320) trials. Given the confidence 
intervals, however, it is clear that even for α = 0.05, we cannot reject the hypothesis that λSNP = 
10-5. Judging from experience in calculating λavg, the mean will continue to fall as the sample size 
increases. 
    95% CI 99% CI 99.9% CI 99.99% CI 
Lower Limit  9.16 x 10
-6 3.91 x 10-6 1.21 x 10-6 3.79 x 10-7 
Upper Limit  2.73 x 10
-4 3.51 x 10-4 4.56 x 10-4 5.56 x 10-4 
5
,
2 errorsˆ 7.56 10  errors/SNP
26453 SNPsMLE SNP
l -= = ´
 
 
Equation VI.11 
Table VI.3  Means and 99.9% confidence intervals for the average and SNP-specific error rates. 
G e n o m e  A s s e m b l y  
 
 
90 
 
VI.8  Computing Time and Code Optimization 
 
With the error rate under control, the practical issue of computing time required to 
sequence a complete genome was addressed. As previously mentioned, memory was a limiting 
factor in the choice of representative genome length. In addition to this restriction, the time 
required to generate, fragment, and reassemble the 10.0 kbp genome was approximately 15 
minutes. In a best case scenario where computing time scales linearly with target genome length 
– a relationship that is, in fact quadratic – this translated into a 3 gbp sequencing time of 2.70 x 
108 seconds, or about 8.65 years. 
The physical computing specifications were inflexible, so code optimization became the 
primary focus of attention. Preliminary alignment script analysis was carried out using the 
MATLAB Profiler tool, which records and graphically displays the number of calls to each 
function, and the total amount of time these calls represent. This revealed the alignment 
algorithm itself (swalign) to be responsible for an overwhelming proportion of computing time 
and memory usage. The Smith-Waterman algorithm, while very robust to any number of input 
errors, is known to be very resource demanding73. Both the alignment time and memory 
requirements scale by the product of the two sequence lengths74.  Given this non-linear 
relationship, decreasing sequence length was expected to produce significant decreases in 
processing time. These lengths were, however, fixed either by nature of by other practical 
considerations. Instead, a hypothetical “short fragment” was created, allowing the alignment 
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process to be divided into a fast position determination step, followed by a much more restricted 
full-fragment alignment.  
First, the beginning 10 bp (1%) of the fragment of interest were aligned to the full 
consensus genome. This enabled the same positioning accuracy and repeatability as full-
fragment alignment, but took a fraction of the time, as it reduced the memory requirements 100-
fold. The alignment starting point was then fed to a second swalign call which aligned the full 
fragment to that particular section of the genome, once again dramatically reducing computing 
time, despite adding extra steps. With this two-phase method is place, computing time for a 10.0 
kbp genome decreased from 15 minutes to 15 seconds – a 60-fold reduction. 
The code was further optimized according to the MATLAB standards outlined in 
“Techniques for Improving Performance,” by replacing all non-essential cell arrays with 
matrices, as MATLAB cannot accelerate for loops involving cell arrays75. Vectorization of all 
remaining loops, where possible, also increased performance. Finally, the full script and certain 
complex operations within it were converted to functions, allowing MATLAB to more 
efficiently load them into memory before execution. Computing time was further reduced from 
15 seconds to less than 5 seconds for a 10.0 kbp target genome at 9.00-fold multiplicity. 
Target genomes up to 1.0 megabases in length were evaluated using the final program. 
Computing time was approximately 3.1 hours for full assembly, with an average error rate of 8.5 
errors per genome (n = 2). This is a significant improvement over the original 10.0 kbp targets, 
and primarily serves to demonstrate the program’s much-improved memory utilization. 
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(The complete simulation script, including subroutines, can be found in Appendix E.) 
VI.9  Data Collection and Processing 
Each sequencing station will be directly connected to a signal acquisition server in the 
adjacent room. This unit will compare the frames of the two EMCCD cameras, identify the 
fluorophores in each pixel, and convert the frame-based data into time-series data. This is then 
translated into a nucleotide sequence by standard signal processing techniques and sent directly 
to the genome reassembly server, rather than being stored. By not storing the fragments until a 
complete set is generated, both sets of computers are utilized continuously, and no precious 
processing time is wasted.  
The genome reassembly servers are extraordinarily sophisticated, and were selected for 
their exceptional memory efficiency and processing bandwidth. The sheer volume of data 
passing through them in a single day demands such high-performance features. Local sequence 
alignment speed, in particular, is particularly responsive to memory access rates and 
multithreading capability. Indeed, successful reassembly is achieved only by minimizing the 
time required by each individual task while maximizing the number of tasks that can be 
performed simultaneous. Just as parallel operation is central to the overall process design, the 
individual genome fragments are distributed to the many subunits of a multiple-core processor. 
But with the complexity of modern computing systems, the result of this parallelization is not 
always obvious, and deserved a more rigorous treatment.  
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A preliminary assessment has been based on the properties of the reassembly simulation, 
providing an estimate of the total computation required. Standardized performance benchmarks 
were then used to more precisely define acceptable system specifications. 
VI.10  Computational Demands 
Using the finalized version of the assembly program described in Section VI.5, the 
functional relationship between target genome length and alignment time was determined. Rather 
than calculating total, single CPU processing time, however, the process was examined at the 
single-fragment alignment level. That is, the time required to align a single 1.0 kbp fragment was 
evaluated as a function of reference genome length. As shown in Figure VI.5, this effect is 
linear, and has the form:  
where time is in seconds, and genlength is the reference genome length in kilobases. In this case, 
the intercept was set to zero, as the time required to create and manipulate empty matrices is 
negligibly small with respect to any non-trivial alignment operations.  
0.00021time genlength= ×
 
2 0.9999R =
 
Equation VI.14 
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 These alignments were performed on an ordinary desktop computer with a 2.4 GHz Intel 
Core 2 Duo 6600 processor and 2.0 GB RAM.  Given the relatively low computational power of 
this system, the total time required to align a 1.0 kbp fragment to a 3.0 gbp genome (3,000,000 
kbp) was determined to be 630 seconds. Assuming a 3-fold increase in calculation speed could 
be accomplished by translating the code into a more efficient language (such as C/C++), 210 
seconds could, in practice, be realized. Properly scaled by the number of fragments, this 
translates into a total genome reassembly time of 9.72 x 1010 seconds, or approximately 3,000 
years at 9-fold coverage multiplicity (see Appendix A for detailed calculations). This value is 
obviously and obstacle with a successful business model, and can only be overcome by way of 
extraordinary computational resources, especially those that allow high-speed, massively-parallel 
task execution.  
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Figure VI.5 The time required to align a single, 1 kbp fragment to a reference 
genome of variable length. The line is a least-squares regression fit, with R2 = 0.9999. 
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VI.11  Multi-Processor Speed-Up and Amdahl’s Law 
The decrease in processing time afforded by the use of multiple processors (or multiple 
processor cores) is fundamental to data-intensive computing strategies. In order to best 
understand the benefit of a multiple-CPU approach, each computational step in the overall 
sequencing process has been analyzed and separated into its “serial” and “parallelizable” parts. 
Those designated “serial” must be performed in order, as each operation requires input from the 
one before. Any tasks that can be accomplished independently are said to be “parallelizable,” and 
to the extent that expenses allow, are simultaneously addressed by multiple processing units. 
The multiplicative factor by which performance in increased when additional processors 
are added is referred to as “speedup,” and can be calculated using Amdahl’s Law. This formula 
expresses speedup, S, as a function of the number of processing units available, N, and the 
fraction of the task that can be parallelized, P: 
1
(1 )
S PP
N
=
- +  
 
Equation VI.15 
If 75% of an operation can be parallelized, for example, and it is divided among 4 processors, the 
calculation speed is expected to increase 2.3 times. This is equivalent to saying that the time 
required to complete the operation would decrease 2.3-fold. 
The alignment routine itself is responsible for an overwhelming majority of the total 
computing time. In fact, as the genome length becomes very large, the fraction of the computing 
time required by this segment of the program goes to approaches unity. Fortunately, this process 
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is almost 100% parallelizable, i.e., P ≈ 1. Each single-fragment alignment is completely 
independent of the others, with the only interaction occurring in the final vote counting 
procedure. Therefore, each computation-intensive alignment task could be delegated to a 
separate processing unit. In this unusually clear-cut case, each additional processor is expected to 
increase the overall processing speed by the same amount, and none of the diminishing returns 
modeled by Amdahl’s law will be encountered. 
VI.12  System Selection 
 In order to reduce the overall data processing time to a single day, a bank of IBM p560 
Express servers will be utilized. These units are distinguished by remarkably high processor 
bandwidths, large L1 and L2 caches, and most importantly, several independent processing 
cores. They are also designed for practicality – being extraordinarily energy efficient and 
compact. As shown in the previous section, the time required to align a 1.0 kbp fragment to a full-length target genome on a typical office computer is: 
 
 Assuming the use of a lower-level programming language increases performance 3-fold, the time required would be 210 seconds.   A single-core p560 server is at least 10,000 time faster than the computer used in the above calculation, as measured by IBM’s commercial processor workload (CPW) index. (The scale for this metric is normalized such that the processing speed of a midrange IBM 
60.00021 (3 10  kbp) 630 spctime = × ´ =
 
Equation VI.16 
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System i  server is defined to be equal to 1.00). The server model selected also has eight independent CPU cores. Since the alignment routine is almost 100% parallelizable, processing speed is increase by the factor: 
1
1 lim   8
(1 )
8
P
S PP
®
æ ö
ç ÷
= =ç ÷
ç ÷- +
è ø
 
 
Equation VI.17 
The maximum final genome assembly time at 9.00-fold multiplicity is therefore: 
VI.13  Conclusions 
 While the assembly of a full human genome is, indeed, a complex undertaking, it has 
been demonstrated not only to be feasible, but adherent to PennBio’s quality standards, and 
consistent with single-day sequencing operations. The alignment program has been proven 
effective and efficient, and has itself validated the probabilistic sequencing models developed. 
Given sufficient computing resources – which are well within reason and budget – this program 
can be run from start to finish in approximately 19.7 hours, as shown above, leaving a generous 
margin for technical difficulties or delays. As a whole, the quantitative evidence provided in this 
chapter has been fundamental to the practical evaluation of the PennBio sequencing approach, 
and  ultimately, the viability of its business model. 
9.00 (210 s/frag) (3,000,000 frag) 1(70,875 s) 19.7 hr
10,000 (8 cores) 3600 s/hrserver
t × × æ ö= = × =ç ÷× è ø  
 
Equation VI.18 
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VII. Financial Analysis 
 
While the previous sections discussed the biochemical and technical aspects of this 
project, it is imperative to analyze the financial aspect of the technology to determine whether 
the project is financially feasible. If there is no existing market and no cash can be generated, no 
investors would fund this project. Consequently, the technology would not be exposed to the 
public. The financial analysis will show that the project is profitable. It will explain how that 
decision was determined using NPV and MIRR analysis, and how those figures were calculated. 
It is important to note, however, that these valuations are based on projected earnings, which in 
turn, are based on several assumptions.  
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The analysis begins with revenue projections based on the genomic throughput and price. 
Because the entire model depends heavily on the revenue, a separate sensitivity analysis is done 
on the genome price. Next, the total costs and depreciation are explained. Knowing these two 
elements leads us to build an income statement. But because the income statement shows 
earnings, and we want free cash, we want to adjust those earning figures into cash figures. To do 
so, we then examine working capital and other cash affecting items.  
Once we have the projected free cash flows, we can then value the company by 
combining terminal value analysis and discounted cash flow analysis. Next, we do a rate of 
return analysis for the investors. Because our project involves two rounds of investments from 
two separate investors (series A and series B), this section becomes a little trickier than the 
conventional analysis. To simplify the complications created by the multiple investments and 
investors, we conduct an equity stake analysis. This will then complete our return of rate analysis 
for the two groups of investors. Having completed all these explanations, we will put everything 
together onto a single page spreadsheet. 
Finally, we discuss multiple what-if scenarios and how that impacts the bottom line. The 
scenario analysis will also involve a genome price sensitivity analysis to determine at which 
point the entire project would lose money.  
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VII.1 Market and Revenue Projection 
The genome sequencing market is a relatively new and volatile market, originally tailored 
to high net worth individuals. Currently, one existing company, Knome®, is charging $100,000 
per client. Furthermore, due to technological improvement incentives like the Archon X Prize 
competition, technology can be expected to improve. If that were the happen, costs would 
significantly drop, and the price charged to clients would also fall dramatically. Little 
information is known about sales volume, but even if it were known, the current economic 
recession may render that figure irrelevant. Consequently, revenue projections are difficult to 
nail down because genome sequencing is not a mature and predictable market.  
For purposes of illustration, we will assume that our genome price is $10,000 for the next 
several sections. Later on, we will conduct a sensitivity analysis on this price because the entire 
financial analysis is heavily dependent on this figure. We also assume that 100% of our design 
capacity is to sell the throughput of 3000 genomes per year: That is, our design capacity would 
allow the company to gross $30MM per year.  
The growth and development of the company fall into four stages: the research stage, the 
scale up stage, the sales stage, and the terminal stage. During the research stage, scientists 
develop a working prototype. There is no revenue and all the needed capital is provided by the 
series A investor. Next, the scale up stage is where a working prototype has been developed, at 
which point series B investors fund the rest of the necessary capital. New staff is added and there 
is a step up increase after the company starts to make sales at a percentage of the design capacity. 
F i n a n c i a l  A n a l y s i s  
 
 
102 
 
Ideally, this figure will be 50% of nominal capacity. After that, the sales stage is when the 
company is fully functional and makes 100% of design capacity. Grown sufficiently, the 
company makes the most money in this stage. Finally, the terminal stage is how the company 
will end. A terminal value of the company will be calculated based on the prior free cash flow 
projection. However, because there are multiple scenarios in the terminal stage, this will be 
discussed in more detail in a later section.  
Ideally, the research stage will take one year, the scale up stage another one year, the 
sales stage three years, and the terminal stage will have one terminal value associated with it. 
Because the genome sequencing market is a volatile, technology-related market, the company 
will have a short lifetime. 
The following table summarizes revenue projections. 
Revenue Projections 
Year 2010 2011 2012 2013 2014 2015 
  30000 
Stage Name Research Scale Up Sales Sales Sales Terminal 
Design Capacity 0% 50% 100% 100% 100% 100% 
    
Revenue  
           $  
-  $ 15,000.0  $ 30,000.0  $ 30,000.0  $ 30,000.0  Terminal Value 
 
Table VII.1  Revenue projections for the following 5 years. ($ in thousands). 
 
 
F i n a n c i a l  A n a l y s i s  
 
 
103 
 
It should be noted that inflation is ignored from all financial analysis. The inflation 
calculations are unnecessary and are only relevant in settings experiencing hyperinflation. In 
fact, the Financial Accounting Standards Board determined in 1986 that inflation accounting is 
unnecessary for financial statements. 
VII.2 Costs, PPE, Depreciation 
There are multiple, different costs associated with running PennBio. The costs can be 
divided into four categories: research equipment purchase, research annual cost, sales equipment 
purchase, and sales annual cost. The research equipment purchase includes all necessary 
laboratory equipment for developing a working prototype. This includes microscopes, 
computers, stations, EMCCD, etc. The research annual cost is how much the company spends 
during the research stage. This mainly includes salary and rent. The sales equipment purchase is 
the rest of the laboratory equipment purchased once a working prototype has been developed. 
This equipment is used to scale up production. The sales annual cost is the annual burn rate of 
the company when the company is able to generate revenue. This burn rate is significantly higher 
than the previous burn rate: In addition to salary and rent, inventory costs, research and 
development costs, and sales costs have been added. These cost figures are summarized in table 
X.2.  
The series A investors are paying for the research equipment purchase and one year’s 
value of research annual cost as an initial fund. Because the research stage is the riskiest stage 
(developing new technology), the series A investors are usually wealthy angel investors. In this 
project, the series A investment comes to a total of $1.2MM.  
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The series B investors come to invest once the risk of research has been reduced: only 
when a working prototype has been developed, do the series B investors give funds to scale up 
production. Their investment will be used for the sales equipment purchase, and 3 months worth 
of salary, rent, and inventory, assuming the company will reach 50% of design capacity. The rest 
of the salary, rent, and inventory will be funded by the revenue generated, but 3 months worth of 
capital should be enough for the company to stay liquid. The series B investment comes to a total 
of $3.5MM, which will be funded ideally one year after the series A investment, or whenever the 
research stage is finished. 
The labor costs for the research stage and the non-research stages differ. During the 
research stage, the company must try to minimize all forms of cost, and salary is no exception. 
Workers consist of a single secretary and four senior scientists, one of whom will also function 
as a chief technical officer (CTO). In addition, because salary costs are large, and the series A 
investor is trying to minimize his capital’s exposure to unnecessary risk, the scientists and series 
A investor have come up with an agreement: the scientists will receive 70% of their ordinary 
salary until a prototype is developed, in exchange for 10% of the company. Normally, in any 
venture, the investor receives about 85% of the company to justify for risk, especially with 
people inexperienced with entrepreneurship. But because this is a biotechnology company, and 
biotech companies carry significantly higher risk, the series A investor feels he must receive 
90% instead. Once a prototype has been developed, the scientists will receive their full salary. 
The labor costs after the research stage are significantly higher: a CEO, junior scientists, 
salespeople, and an IT specialist have been added.  
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The rental costs for the research stage is lower than the non-research stages. Space is 
minimized during prototype development but once it’s been developed, the space required for 
sequencing and the molecular biology lab are expanded. 
The inventory costs include only the SMRT chips and reagents. These costs depend on 
the design capacity: at 100% of design capacity, the total inventory cost will be $690,000. At 
50% design capacity, the chip costs will be half that. Since the research phase only involves 
prototype development, and not revenue generation, there are no inventory costs.  
Finally, the operating costs include research and development, and sales costs. These 
costs only apply during the stage beyond the research stage. They have been estimated as a 
percentage of revenue. 
The Gantt chart in Figure VII.1 on the facing page outlines a potential two day 
operational period scenario in order to determine the number of technicians required for optimal 
sequencing throughput.  In consideration of the number or lab technicians required in order to manage the throughput of the system, it is important to consider the amount of time required for the preparation of the key parts solutions required for sequencing.  The most important steps are the genome extraction and amplification, and the preparation of the waveguides for sequencing.  Since the genome isolation requires a 16 hour incubation period for maximum extraction, it is unnecessary to wait for incubation during the work day.  Therefore, it is best to prepare the DNA solution at the end of the work day, and then allow for incubation overnight.  Upon returning to work the next morning, the amplified genomic DNA is ready for use.  It is important to note that a 
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 large number of samples can all be prepared in one batch, so that this time scale assumes the preparation of approximately 2 days worth of DNA for sequencing for one day of DNA extraction.   
The preparation of a single chip, including immobilization of the DNA polymerase and the loading of the DNA takes approximately 40 minutes.  In order to safely meet throughput requirements, 13 chips must be prepared in one day.  As Figure VII.1 demonstrates, it is possible for a single technician to prepare all 13 chips in a single day, not accounting for necessary breaks.  Once the chips are prepared, they can be set in the sequencing apparatus and allowed to run overnight.  Assuming a very efficient lab technician that does not eat and works 20 minutes of overtime, it is possible that in this scenario, one lab technician can handle the throughput required to meet the sequencing goals.  However, in order to account for potential complications and problems, another lab technician should be available so that the work load can be divided, easily meeting the throughput required.  Also, this scenario assumes that several chips cannot be prepared at once.  Considering the small size and standardization of the chips, it is reasonable to assume that several, if not all, of the chips used in one day cannot be prepared at the same time, up to the point of the addition of the DNA, which is actually the final step in the preparation of the chips.   Assuming this, two lab technicians should be sufficient to handle the throughput requirements. 
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The company will use a 5 year MACRs depreciation schedule because the accelerated tax 
schedule will provide the company with tax savings. Depreciation is a non-cash expense but it 
still affects the pre-tax income, from which taxes are deducted. If the pre-tax income decreases, 
taxes will also decrease. And tax, unlike depreciation, is a cash expense. An accelerated 
depreciation schedule for short lived projects like this will have a significant impact on the NPV 
and MIRR analysis. The depreciation percentages for MACRS in order are 20%, 32%, 19.2%, 
11.52%, 11.52%, and 5.76%. 
Depreciation Schedule 
MACR Tax Schedule: 20.00% 32.00% 19.20% 11.52% 11.52% 
Year 2010 2011 2012 2013 2014 
Series A Equipment 
        $ 
708.3  
Depreciation      $ (141.7)      $ (226.7)      $ (136.0) 
          $ 
(81.6) 
Series B Equipment     $ 2,676.8  
Depreciation      $ (535.4)      $ (856.6) 
        $ 
(513.9) 
Beginning Net PPE 
               $  
-   
        $ 
708.3      $ 3,243.4      $ 2,481.4        $ 1,488.9  
PPE Purchased/(Sold) 
           
708.3         2,676.8  
                   
-   
                   
-   
                     
-   
Less: Total Depreciation 
                   
-   
         
(141.7) 
         
(762.0) 
         
(992.6) 
     
(595.5) 
Ending Net PPE 
        $ 
708.3      $ 3,243.4      $ 2,481.4      $ 1,488.9            $ 893.3  
 
Table VII.4  Depreciation Schedule using the 5 year MACRs schedule. ($ in thousands). 
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The series A equipment is the research equipment purchase, and the series B equipment 
is the sales equipment purchase. The ending net PPE figures are balance sheet items and 
represent how much property and equipment the company owns. The total depreciation is what 
will appear on the income statement and will decrease the pre-tax income. In a later section, we 
will explore a what-if scenario of when the research stage takes two years instead of one. In that 
case, the series B equipment and its depreciations would simply be shifted to the right one year 
and the total depreciations would be changed as well. 
VII.3  Income Statement 
 
Income Statement 
Year 2010 2011 2012 2013 2014 
Revenue            $  -      $ 15,000.0     $ 30,000.0     $ 30,000.0     $ 30,000.0  
Cost of Sales      (172.6)           (643.6)           (988.6)           (988.6)           (988.6) 
Gross Profit      (172.6)       14,356.4        29,011.4        29,011.4        29,011.4  
Operating, SG&A 
Expenses      (292.0)       (2,380.0)       (3,730.0)       (3,730.0)       (3,730.0) 
Depreciation 
                
-            (141.7)           (762.0)           (992.6)           (595.5) 
Pre-Tax Income      (464.6)       11,834.7        24,519.4        24,288.8        24,685.9  
# Tax @ 40% 
        
185.8        (4,733.9)       (9,807.8)       (9,715.5)       (9,874.3) 
Net Income   $ (278.8)      $ 7,100.8     $ 14,711.6     $ 14,573.3     $ 14,811.5  
Design Capacity  0% 50% 100% 100% 100% 
Margins 
Gross Margin 0.0% 95.7% 96.7% 96.7% 96.7% 
Profit Margin 0.0% 47.3% 49.0% 48.6% 49.4% 
 
Table VII.5  The income Statement showing the gross and profit margins. ($ in thousands). 
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The total costs are divided into cost of sales and operating, SG&A expenses. The cost of 
sales (also known as costs of goods sold, COGS) includes costs that are directly involved in the 
making of the goods. It is a sum of fixed costs and variable costs. The fixed costs include rent 
and overhead because rent and overhead costs do not vary with the number of goods sold. The 
variable costs are the inventory costs because the inventory cost is a function of how many 
genomes are sequenced. Subtracting the cost of sales from the revenue is the gross profit. The 
gross margin is a percentage showing how much money is left from the revenue after paying for 
the cost of sales. The operating and SG&A (Selling, general, and administrative) expenses are 
costs that are associated with managing the business. These costs are mainly salary, but also 
include the research and development cost and the sales cost. Subtracting these new expenses 
and the depreciation gives the pre-tax income.  
Federal taxes are set around 35% but when state tax is added, the tax can be rounded up 
to 40%. In the first year, because the company has actually lost money, the tax figure is positive 
and the company actually receives money from the government. This is called negative taxes, or 
tax shield. Sometimes this does not apply, but we will assume that this holds with our company. 
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VII.4  Working Capital 
 
The income statement led us to net income. But net income is not equivalent to cash. In 
order to get to cash figures, and subsequent NPV and IRR analysis, we need to adjust net income 
for cash items. There are multiple cash items to adjust for. Change in working capital is one of 
them.  
Working capital is how much capital a company needs to operate normally. If a company 
makes $1000, it can’t give all of it to the owner: a portion of it has to be allocated for the 
company to run its day-to-day operations. This allocated cash is the working capital and it can be 
described as current assets minus current liabilities. Current assets are things the company has 
that can be converted to cash quickly. Current liabilities are bills and debts the company has to 
pay quickly. Working capital is current assets minus current liabilities because it is the money 
left over after having paid all its imminent bills. 
There are four main working capital items we will work with: accounts receivables, 
inventory, accounts payable, and cash reserve. Accounts receivables are earnings that haven’t 
received cash payment yet. For example, after making a sale, the company records its earnings 
even when it hasn’t received cash payment yet. The client usually has about 30~60 days to pay. 
We will choose 30 days. Because all account receivables convert into revenue: 
                   =        ($)    ∗ 1    365    ∗ 30     
 
Equation VII.1 
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 Inventory is what the company needs to produce the goods it sells. In our case, they are 
the SMRT chips and reagents. Our company will buy new inventory every month. 
         =               ($)    ∗ 1    365    ∗ 30     
 
Equation VII.2 
Accounts payable is the opposite of accounts receivable: they are bills the company 
records (and subtracts from revenue) but haven’t handed in the cash yet. We will pay bills every 
30 days. Normally, in the following equation, cost of sales is used instead of rent and operating 
cost, but because we have more detailed information, we can modify the equation. Cost of sales 
usually has rent, operating costs, and inventory costs all buried inside so many people use cost of 
sales as a proxy. Because all account payables turn into rent and operating costs: 
                =     +                ($)    ∗ 1    365    ∗ 30     
 
Equation VII.3 
Cash reserve is cash on hand needed to pay for future salary. We will reserve 3 months worth of 
salary. 
   ℎ        =       ($)    ∗ 1    12    ℎ ∗ 3    ℎ  
 
Equation VII.4 
Change in working capital items change net income into cash. 
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Working Capital 
Year 2010 2011 2012 2013 2014 
Working Capital Item Estimates 
Accounts Receivable 
         $  
-       $ 1,232.9      $ 2,465.8     $ 2,465.8     $ 2,465.8  
Inventory 
             
-   
              
28.4  
              
56.7  
            
56.7  
            
56.7  
Accounts Payable 
       
24.5             135.5             246.5  
          
246.5  
          
246.5  
Cash Reserve 
       
73.0             257.5             257.5  
          
257.5  
          
257.5  
Changes in Working Capital 
(Increase)/Decrease in A/R 
         $  
-     $ (1,232.9)   $ (1,232.9)              $  -                $  -   
(Increase)/Decrease in Inv 
             
-   
           
(28.4) 
           
(28.4) 
                  
-   
                  
-   
Increase/(Decrease) in A/P 
       
24.5             111.0             111.0  
                  
-   
                  
-   
(Increase)/Decrease in C/R     (73.0) 
         
(184.5)                    -   
                  
-   
                  
-   
Total Change in Working Capital  $ (48.5)   $ (1,334.8)   $ (1,150.3)              $  -                $  -   
 
Table VII.6  Working Capital and Change in Working Capital. ($ in thousands). 
 
Any increase in assets will decrease cash. It makes sense because the company needs to 
spend money to buy things. Any decrease in assets will increase cash because selling equipment 
or any other asset results in cash.  An increase in liability also increases cash. If a company 
borrowed money from a bank, it has more money to spend, before having to spend it back. A 
decrease in liability results in decrease of cash because the company has to spend cash to pay 
back debt.  
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An increase in account receivable since last fiscal year should decrease cash because net 
income has taken this account but the company hasn’t actually received the money yet. By next 
fiscal year, however, the company will have been paid, which is reflected by a decrease in 
accounts receivables (assuming no additional A/R accrues). An increase in inventory decreases 
cash because the company needs to spend cash to buy inventory. An increase in accounts payable 
increases cash because net income is revenue minus accounts payable, but the company hasn’t 
paid the bill yet. An increase in cash reserve decreases cash because cash has to be held back to 
pay future salary and that cash can’t be used to pay the owners or else the company will cease to 
operate normally.  
Two other cash items need mentioning. Purchasing PPE (plant, property, and equipment) 
decreases cash immediately. However, a PPE purchase isn’t shown on the income statement. 
Instead, it is slowly amortized. This is because the income statement reflects the company’s 
operational efficiency, which doesn’t necessarily involve one-time cash expenses. Selling of 
equipment is the same: it immediately generates cash, but it isn’t part of revenue because 
revenue only reflects the company’s natural operations. Selling unwanted equipment isn’t part of 
operations: it’s a one-time thing.  
Issuing common stock is the same. Issuing common stock to investors (series A and 
series B investors) immediately generates cash but isn’t part of revenue. Repurchasing existing 
shares from the public market would decrease cash but isn’t reflected on the income statement.  
All cash items are found in the cash flow statement.  
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VII.5  Free Cash Flow, Terminal Value 
After getting change in working capital and other cash items from the cash flow 
statement, we can convert net income into free cash flow.  
 
Free Cash Flow 
Year 2010 2011 2012 2013 2014 
Net Income  $ (278.8)      $ 7,100.8     $ 14,711.6  
   $ 
14,573.3  
   $ 
14,811.5  
Cash Flow Statement 
Cash From Operating Activities 
Plus: Depreciation 
           $  
-   
         $ 
141.7          $ 762.0  
        $ 
992.6  
        $ 
595.5  
Changes in Working Capital 
(Increase)/Decrease in A/R 
                
-   
      
(1,232.9) 
      
(1,232.9) 
                    
-   
                    
-   
(Increase)/Decrease in Inventory 
                
-   
            
(28.4) 
           
(28.4) 
         
-   
                    
-   
Increase/(Decrease) in A/P 
         
24.5  
            
111.0  
            
111.0  
                    
-   
                    
-   
(Increase)/Decrease in C/R 
       
(73.0) 
         
(184.5) 
                    
-   
                    
-   
                    
-   
Total Change in Working Capital 
       
(48.5) 
      
(1,334.8) 
      
(1,150.3) 
                    
-   
                    
-   
Cash From Investing Activities 
(Purchase)/Selling of Equipment     (708.3) 
      
(2,676.8) 
                    
-   
                    
-   
                    
-   
Cash From Financing Activities 
Issuance of Common Stock 
    
1,200.0          3,500.0  
                    
-   
                    
-   
                    
-   
Free Cash Flow 
    $ 
164.5       $ 6,730.9     $ 14,323.4  
   $ 
15,565.9  
   $ 
15,407.1  
 
Table VII.7  Free Cash Flow from Net Income. ($ in thousands). 
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The free cash flows are used for NPV and IRR analysis because they represent real cash 
received by the owners.  
Before conducting NPV and IRR analysis, however, we need to determine the terminal 
value of the company. We accomplish this by using the perpetuity growth model: 
              =    ℎ     ∗ (1 +  ) −   
 
Equation VII.5 
 
The cash flow is the last free cash flow. The parameter g is 
the growth rate of the cash flow and the company. The 
parameter r is the discount rate. This terminal value can be  
described as the present value of all the continuing future 
cash flows. This concept is highly theoretical because it 
assumes that future cash flows are predictable. Note: when 
g = 0, the equation simplifies into CF / r, which is the basic 
perpetuity model.  
  
Terminal Value 
Last Free Cash 
Flow 
           $ 
15,407.1  
Discount Rate 25% 
Growth Rate Terminal Value 
15% 
         $ 
154,070.6  
0% 
           $ 
61,628.2  
-15% 
           $ 
38,517.6  
Table VII.8 Terminal Value Examples 
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VII.6  NPV Valuation 
The net present value is a mathematical model used to describe how much richer one 
would become today if he were to undertake the investment. It is the sum of all the present 
values of every cash flow, which in this case, is the free cash flow and the terminal value. It is a 
theoretical model that is heavily dependent on the discount rate.  
NPV Calculation @ 25% 
Year 2009 2010 2011 2012 2013 2014 Terminal Value 
T 0 1 2 3 4 5 6 
Free Cash 
Flow $ 164.5  $ 6,730.9  $ 14,323.4  $ 15,565.9  $ 15,407.1     $ 61,628.2  
Discount Rate 50% 25% 25% 25% 25% 25% 
Present Value $ 109.7  $ 4,307.8  $ 7,333.6  $ 6,375.8  $ 5,048.6  $ 16,155.5  
Investments $ (1,200.0) $ (3,500.0) 
Discount Rate 0% 25% 
Present Value $ (1,200.0) $ (2,800.0) Sum of All Present Values (NPV) $ 35,330.9  
 
Table VII.9  Net Present Value Calculation Using Discount Rate of 25%. ($ in thousands). 
 
The discount rate used depends on the industry. The riskier the industry, the higher the 
discount rate is. Because the biotechnology industry is risky and unpredictable, the discount rate 
used will be 25% and 30%. Both will be used to create a range of multiple NPVs.  The discount 
rate during the research stage, however, will be 50% because developing new technology is 
much riskier. Table 8 summarizes the calculations using a discount rate of 25%. 
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In order to calculate the net present values, all the projected free cash flows and terminal 
value are discounted back into present values. Those present values are then summed. Next, we 
have to subtract out the present values of the cost of the project – the initial investments. Our 
calculation becomes trickier because we have two rounds of investments at two different times 
from two different investors. Some qualitative reasoning is required. The present value of the 
first investment, the series A investment of $1.2MM, is equal to itself because it is not a future 
cash flow: it is a cash outflow that occurs in the present. The second investment, the series B 
investment of $3.5MM, occurs at the end of 2010, when a working prototype has been 
developed. Unlike the first cash inflow that is discounted at a rate of 50%, the series B 
investment is actually discounted at a rate of 25%. This is because the purpose of the 50% 
discount rate was to take into account the extraordinary risk of developing new technology. 
Because series B is funded only when that extra risk is taken away, it is discounted at 25%, not 
50%. 
Also note that the terminal value of the company is also discounted to the present. This is 
because the terminal value is a future projected value. We have assumed that the growth rate will 
be 0%. The sum of all the present values is the net present value: it is called net present value 
because it adds all the positive future cash flows, and the present negative investments to get a 
net sum. This number tells us that undertaking the PennBio project will make the investors 
$35MM richer today. Of course, keep in mind that this is only a model and it depends heavily on 
several assumptions. It is good practice to do multiple analyses under different scenarios and 
assumptions. 
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VII.7  Equity Shares 
There is another profitability measure called the IRR, but because there are two different 
investors, each investing at two different times, we need to create an internal bookkeeping of 
how much equity each group of investors own. To clarify, how much of the free cash flows do 
the series A investors get to keep, and how much do the series B investors keep? 
To get an initial picture, we 
compare how much the two investors 
have put into the project. The series 
A investors put in $1.2MM at the 
beginning and the series B investors 
put in $3.5MM one year later. 
Because of the time difference, the 
series A investment needs to be 
discounted forward by 50% to compare the two numbers correctly.  
From this result, it can be argued that the series B investors should keep 66% of the 
company once they come in. On the other hand, because the series A investors have put in more 
sweat equity and feel that they undertook more risk that the discount rate doesn’t quite cover, 
both could agree that the series A investors will receive more equity. However, for the sake of 
simplicity and because the issue of sweat equity is a very subjective one, we will avoid that here. 
The series B investors will receive 66% of equity, the series A investors will keep 90% of the 
remaining 34%, and the scientists will keep 10% of the remaining 34%. In the case where the 
Percentage of Investments 
Investment 
FV 
Investment Percentage 
Series A 
Investors     $ 1,200.0  
          $ 
1,800.0  34% 
Series B Investors        3,500.0  
             
3,500.0  66% 
Total 
          $ 
5,300.0  100% 
Table VII.10 Comparing Percentages of Investments. ($ in thousands). 
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research stage takes two years, the series A investment will be discounted forward twice by 50%: 
series B investors would receive 54%. Table VII.11 summarizes company ownership. 
Equity Percentage 
Year 2010 2011 2012 2013 2014 2015 
Scientists 10% 3% 3% 3% 3% 3% 
Series A 
Investors 90% 31% 31% 31% 31% 31% 
Series B 
Investors 0% 66% 66% 66% 66% 66% 
Total 100% 100% 100% 100% 100% 100% 
NPV @ 25% $ (1,090.3) $ 417.5  $ 7,751.0  $ 14,126.8  $ 19,175.4  $ 35,330.9  
Investments 
      
(1,200.0) 
             
(2,800.0) 
Shares Values vs. Time 
Scientists $  -   
                  $ 
14.2  $ 263.2  $ 479.8  $ 651.2  $ 1,199.9  
Series A 
Investors 
                    
-   
                   
127.6          2,369.2  4,318.0  5,861.2  10,799.2  
Series B 
Investors   -   275.7  5,118.6  9,329.0  12,663.0  23,331.7  
Total $  -   $ 417.5  $ 7,751.0  $ 14,126.8  $ 19,175.4  $ 35,330.9  
 
Table VII.11  Equity Percentage and Share Values of Owners. ($ in thousands). 
 
By calculating the NPV values at each year, we can also calculate each owner’s share value as a 
function of time.  
Defining equity percentage is an important bookkeeping task because percentage of 
ownership determines how much of the free cash flows generated each group will get to keep. 
Using that information, we can conduct a rate of return analysis. 
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VII.8  MIRR Analysis 
Conventional rate of return analysis uses the IRR (internal rate of return) figure. 
However, there are many flaws in that model. Consequently, using IRR for our analysis would 
yield highly overstated and inaccurate results, especially in projects with large positive cash 
flows. In using the IRR, the calculation assumes that the free cash flows will be reinvested at the 
rate being calculated. This is a critical mistake because in the PennBio investment, there are only 
two rounds of investments and none of the free cash flows are being reinvested. In fact, 
McKinsey consultants advise avoiding using the IRR. 
The alternative rate of return metric will be the MIRR (Modified internal rate of return). 
In this metric, we must specify the finance rate and the reinvest rate. The finance rate is the APR 
(Annual percentage rate) the company would have to pay to debt lenders if there are any negative 
cash flows. The reinvest rate is the rate the owners would receive on the positive cash flows. For 
the finance rate, we will assume a standard 4.4% on a bank term loan. For the reinvest rate, we 
will assume a 4.9% return. It is the current yield on a 3 month and 6 month US Treasury bill, 
which can be seen as the risk free rate. Alternatively, we could use a higher reinvest rate since 
the investors can be assumed to experienced enough to earn more than the risk free rate, 
especially if they are investing in the risky biotech industry. However, we chose the risk free rate 
to be conservative in our profitability analysis.  
The MIRR calculations are simple: First, the investment is defined. Then all the free cash 
flows the investor would receive are divided by the equity percentage. An MIRR can be 
determined from those figures. The following table summarizes the calculations. 
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MIRR Calculations 
Year 2010 2011 2012 2013 2014 2015 
Free Cash Flows $ 164.5  $ 6,730.9  $ 14,323.4  $ 15,565.9  $ 15,407.1  $ 61,628.2  
Equity 
Percentage 
Series A 90% 31% 31% 31% 31% 31% 
Series B 0% 66% 66% 66% 66% 66% 
Cash Flows 
Investmen
t Divided Free Cash Flows 
Series A  $ (1,200.0) $ 148.0  $ 2,665.4  $ 5,672.1  $ 6,164.1  $ 6,101.2  $ 24,404.8  
Series B  $ (3,500.0) $ 3,769.3  $ 8,021.1  $ 8,716.9  $ 8,628.0  $ 34,511.8  
Series A MIRR 77% 
Series B MIRR 87% 
 
Table VII.12  MIRR Calculation. Finance rate at Term loan APR of 4.4%, reinvest rate at 6-month T-bill of 4.9%. ($ in 
thousands). 
 
Note that an IRR calculation would yield around 150% returns, a grossly overstated 
figure. Also, the series B cash flow has one less term. This is because the series B investors came 
in one year after the series A investors did.   
To summarize the first part of our financial analysis, we created a pro forma income 
statement, adjusted to get free cash flows, and then used those to arrive at an NPV and MIRR 
analysis. The following page summarizes everything we have done so far. There are two terminal 
values: the one on the top uses a discount rate of 30% and the one on the bottom uses 25%.
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VII.9  What-If Scenarios 
So far, the previous financial analysis holds under certain assumptions. But what if those 
assumptions aren’t true? What if the project undergoes certain deviations? Then what will 
happen to our financial analysis? 
To observe, how the project’s profitability would change, different case scenarios were 
defined for the research stage, scale up and sales stage, and the terminal stage. The following 
table summarizes the different case scenarios and their results. 
What-If Scenarios 
Research Stage 
Best Case S1) The start up stage takes one year, as planned.  
Worst Case S2) The start up stage unexpectedly takes two years.  
Scale Up and Sales Stage 
Best Case D1) The first year of sales has 50% of design capacity, as planned. The remaining 
three years run at full 100% capacity. 
Worst Case D2) The first year of sales has 30% capacity. The next year's capacity is 70%. 
The remaining two years of sales have full 100% capacity. 
Terminal Stage 
Best Case T1) The company stays profitable. The revenue stays constant perpetually. 
Middle Case T2) The company starts to decline due to rising competitors.  
15% Earnings decrease 15% each year. 
Worst Case T3) Due to an improved rival technology, customers stop showing up immediately.  
50% Equipments are sold at 50% of face value, a total of $1.69MM. 
Table VII.13  What If Scenarios 
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Scenario Summary 
 
Tree Case NPV @ 30% NPV @ 25% 
Series A 
MIRR 
Series B 
MIRR 
S1 D1 T1 1  $          26,959   $        35,331  77% 87% 
T2 2              22,349             27,758  69% 76% 
T3 3              16,670             19,619  58% 62% 
D2 T1 4              23,025             30,964  75% 84% 
T2 5              18,414             23,392  66% 73% 
T3 6              12,736             15,253  53% 57% 
S2 D1 T1 7              26,733             35,103  58% 81% 
T2 8              22,122             27,530  58% 71% 
T3 9              16,444             19,391  58% 57% 
D2 T1 10              22,799             30,737  54% 78% 
T2 11              18,188             23,164  54% 67% 
T3 12              12,510             15,025  54% 52% 
NPV and MIRR Range 
 
High Medium Low 
(Average of top 3) (Median) (Average of bottom 3) 
NPV $ 33,799.4  $ 22,573.7  $ 13,423.3  
Series A 73% 58% 54% 
Series B 84% 72% 55% 
Table VII.14  Complete NPV and MIRR Summary of 12 What-If Scenarios. ($ in thousands). 
 
Even under these various scenarios, the PennBio project looks very comfortable. A copy 
of all 12 pro forma is provided in Appendix F. One crucial assumption to note here is that all 
these scenarios have the genome price selling at $10,000. As mentioned in the introduction, the 
revenue generation is the most important assumption because all our financial analysis depends 
on it.  
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VII.10  Price Sensitivity Analysis 
We will repeat the same analysis under various genome prices to see under which prices 
the project would lose money. The following table summarizes the results. The genome prices 
range from $10,000 to $500.  
Genome Price Sensitivity Analysis 
NPV MIRR 
Genome Price High  Medium  Low  High A  Medium  Low  High B  Medium  Low  
   $ 
33,799.4  
       $ 
22,573.7  
   $ 
13,423.3  73% 58% 54% 84% 72% 55% 
$ 10,000  $ 33,799  $ 22,574  $ 13,423  73% 58% 54% 84% 72% 55% 
                          
9,000  
          
29,806  
              
19,780  
          
11,628  71% 56% 51% 80% 69% 52% 
                          
8,000  
          
25,797  
              
16,969  
            
9,815  67% 53% 48% 76% 64% 49% 
                          
7,000  
          
21,788  
              
14,157  
            
8,002  63% 49% 45% 71% 60% 45% 
                          
6,000  
          
17,794  
              
11,364  
            
6,206  59% 45% 41% 65% 55% 40% 
                          
5,000  
          
13,785  
               
8,553  
            
4,393  54% 40% 36% 59% 49% 35% 
                          
4,000  
            
9,776  
                
5,737  
            
2,580  48% 35% 31% 51% 41% 29% 
                          
3,000  
            
5,783  
                
2,874  
          
784  40% 27% 23% 41% 32% 21% 
                          
2,000  
            
1,773  
                      
83  
          
(1,029) 28% 17% 13% 27% 18% 10% 
                          
1,000  
          
(2,211) 
              
(2,609) 
          
(2,971) 5% -2% -8% -2% -7% -10% 
                             
500  
      
(3,530.7) 
          
(4,045.7) 
      
(4,402.1) -16% -30% -31% -22% -88% -100% 
 Breakeven 
Price  $ 1,600.0  $ 2,000.0  $ 2,600.0  
  ,553.5  1,951.7  2,582.5  
Table VII.15 Genome Price Sensitivity Analysis for NPV and MIRR. ($ in thousands). 
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As mentioned before, the price of the genome is difficult to nail down. But we see here 
that charging at least $3000 per genome can still make returns. This is a very comfortable price 
margin, especially considering that one of the existing competitors, Knome®, is charging 
$100,000. 
VII.11  Growth Case 
We look at one final scenario. When the company’s margins are healthy, it would be wise to 
expand its operations. This would only happen when the research stage, scale up stage, and the 
development stage occur as planned – that is, a case 1 scenario. This would be the best case scenario. In 
our financial model, we will make the design capacity grow exponentially at 50% during the sales stage: 
the company will operate at a capacity of 100%, 150%, and 225%. Here, the average of the 25% and 30% 
NPV is $54MM, the series A MIRR is 95%, and the series B MIRR is 110%. At the end of Appendix F, 
is the pro forma for this case. 
VII.12  Conclusions 
The entire financial analysis has provided ample evidence to show that PennBio would be 
a profitable investment. Next, the what-if scenarios have shown that the investors would receive 
high returns, even under worst case scenarios. Finally, the sensitivity analysis has revealed that 
an ample price margin exists before the investors lose their capital.  
Of course, financial models are insightful, but they are still models. They help to guide 
the investors and to reduce as much risk as possible. Models do not determine the future. And 
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because no one can predict the future, there will always be a degree of financial risk. But our 
financial analysis has covered as much as possible. One reason why the venture looks so 
profitable is chiefly due to the nature of the market: It is a biotech firm in an early, immature 
market. Not many competitors exist with our technology. And this is typically what one would 
expect in such settings. Until the market matures, profit margins will be remarkably high.  
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VIII.    Conclusions 
 
 The primary objective of this venture was to characterize and develop a novel whole-
genome sequencing technique with a particular focus on accuracy and extraordinary throughput. 
This was achieved through the application of cutting-edge single-molecule, real-time detection 
technology. Fundamental to this approach are several breakthroughs which pushed production to 
new heights while maintaining sequence fidelity. Zero-mode waveguides, which simultaneously 
provide exceptionally high signal-to-noise ratios and the geometric consistency that permits one-
to-one waveguide to pixel mapping, allow for unprecedented clarity in single-molecule 
observation. Novel phospho-linked nucleotides, which emit signal pulses while being 
incorporated into sequenced DNA then go dark as their fluorescent moiety is cleaved from the 
unadultered growing complementary strand, facilitate unparalleled sequence-reads and 
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polymerization rates. Two precision-aligned EMCCD cameras collect this high-quality signal 
and relay it to a powerful server bank, where it is converted into a complete, personal genome 
sequence using a unique two-color ratio approach, and custom-optimized sequence alignment 
algorithms.  
 At full capacity, PennBio can supply 1 genome per SMRT chip station  per day. With a 
mere 13 stations, production  is expected to reach  3,000 full genomes per year. This level of 
throughput well exceeds the industry status quo, and in conjunction with the minimum of capital 
investment per unit output, translates into affordable and readily available genomic data for our 
customers. And at a retail price of $4,000 per genome, we stand to gross up to $12.0 million per 
year in revenues. We offer our investors a unique opportunity to profit financially from the 
relentless advances made every day in understanding and practical use of the human genome.  
Moreover, this financial situation appears to be optimal in the current technological 
environment. Using 1-to-1 polymerase to pixel ratios, and relatively simple optics, we have 
minimized our fixed costs, while the utilization of high-performance enzymes and streamlined 
data analysis maximizes revenue. We therefore do not believe that another whole-genome 
sequencing firm could enter the market and be more profitable than PennBio – not without 
substantial advances in optical detection, computing, and biotechnology. 
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Appendix A:  
Reagent Specifications  
 
A.1 Sequencing-by-Synthesis Reagents 
A.2 Deoxyribonucleotide Fluropentaphosphate Reagents 
A.3 Deoxyribonucleotide Fluropentaphosphates 
A.4 Proteins 
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Sequencing-by-Synthesis Reagents 
 
Species Structure Formula Manufacturer Price ($) 
Biotin 
 
C10H16N2O3S (Various) -- 
Biotin-polyethyleneglycol-trimethylsilane  --  Laysan Bio  480  per 500 mg 
Polyvinylphosphonic acid 
 
(C2H5PO3)n Sigma-Aldrich 215  per gram 
Random Hexamers See individual Nucleotides on page B.2 5’-NNNNNN-3’ Fidelity Systems 22 per 4 µg 
Reaction Buffer (Various) 
50mM ACES: 
C4H10N2O4S 
75mM KC2O2 
5mM 
dithiothreitol: 
C4H10O2S2 
(Various) -- 
Sodium Hydroxide 
 
NaOH The Science Company 11.5  per 500 g 
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Deoxyribonucleotide Fluoropentaphosphate Reagents 
 
Species Structure Formula Manufacturer Price ($) 
Guanine 
 
C5H5N5O Cole-Parmer 25.30 per 25 g 
Adenine 
 
C5H5N5 Cole-Parmer 96.30 per 25 g 
Thymine 
 
C5H6N2O2 Cole-Parmer 47.10 per 25 g 
Cytosine 
 
C4H5N3O  Cole-Parmer  56.60 per 5 g 
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Species Structure Formula Manufacturer Price ($) 
Fmoc-6-aminohexylphosphate  C21H25NO3 AnaSpec 120  per gram 
Anhydrous acetonitrile 
 
C2H3N Sigma-Aldrich 761  per 18 liters 
Anhydrous triethylphosphate 
 
C6H15O4P Sigma-Aldrich 156.50  per 4 liters 
Phospohrus oxychloride  POCl3 Sigma-Aldrich 105  per 100 mL 
Triethylamine 
 
C6H15N Sigma-Aldrich 102  per 2 liters 
Bicarbonate 
 
HCO3
- Sigma-Aldrich 47.30  per 500 grams (NH4+  salt) 
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Species Structure Formula Manufacturer Price ($) 
Methanol  CH3OH Sigma-Aldrich 
40.90  per liter 
Diethyl Ether  C4H10O Sigma-Aldrich 199.50  per 4 liters 
Dimethylformamide 
 
C3H7NO Sigma-Aldrich 24 per 250 mL 
1,1’-Carbonyldiimidazole 
 
C7H6N4O Sigma-Aldrich 36.70  per 10 g 
tributylamine 
 
[CH3(CH2)3]3N Cole-Parmer 35.90 
Phosphoric Acid 
 
H3PO4 Cole-Parmer 47.74  per 500mL (85% sol’n) 
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Species Structure Formula Manufacturer Price ($) 
Magnesium Chloride Cl – Mg – Cl MgCl2 Gallade Chemical 104.96  per 5 g 
Alexa Fluor A555 
 
 Invitrogen 240  per 1 mg 
Alexa Fluor A568 
 
 Invitrogen 240  per 1 mg 
Alexa Fluor A647 
 
 Invitrogen 240  per 1 mg 
Alexa Fluor A660 Not Available  Invitrogen 240  per 1 mg 
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Deoxyribonucleotide Fluoropentaphosphates 
 
Molecular structures of the phospho-linked deoxyribonucleotide pentaphosphates, and their normalized 
fluorescence emission spectra of their fluorophores. The two excitation wavelengths used are indicated 
by arrows (532 and 643nm). Reproduced from Eid, et al. 2009. 
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Proteins: φ29 Polymerase 
 
Reproduced from Berman, et al. 2007. 
Theoretical molecular weight: 66,714 Daltons. 
Quaternary Structure: Monomeric. 
Manufacturer: New England Biolabs 
Source: An E. coli strain that carries the phi29 DNA Polymerase gene from bacteriophage phi29 
Cost: 1,250 units at 10,000 units/ml for $244.00  
One unit is defined as the amount of enzyme that will incorporate 0.5 pmol of dNTP into acid 
insoluble material in 10 minutes at 30°C. 
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 Streptavidin 
 
Reproduced from Berman HM, et al. 2000. 
Theoretical molecular weight: 52,800 Daltons. 
Quaternary structure: Tetrameric. 
Manufacturer: New England Biolabs 
Source: Streptomyces avidinii 
Cost: 1 mg as 1 mg/ml for $56.00 
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Appendix B:  
DNA Extraction and Isolation  
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Protocol provided by QIAGEN: 
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Appendix C:  
Synthesis of Phospho-Linked 
Nucleotide Pentaphosphates  
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 Reproduced from J. Korlach et al. 2008 The synthesis is described using Alexa Fluor 488-aminohexyl-dG5P (A488-dG5P) as an example. 
Fmoc-6-aminohexylphosphate: Fmoc-6-aminohexanol (1 g, 2.94 mMoles) was co-evaporated with anhydrous acetonitrile (2 20ml) then suspended in 10 ml anhydrous triethylphosphate. Phosphorus oxychloride (550 μl, 5.88 mMoles, 2 eq.) was added to the stirring suspension. After 2 hours, HPLC showed disappearance of the Fmoc-aminohexanol. The reaction was quenched by the addition of 100 ml 0.1M triethylamine bicarbonate (pH 6.8) and stirred for 30 minutes. The compound was purified by reverse phase HPLC on a Waters Xterra C18 RP 30 100 column using an acetonitrile gradient in 0.1M triethylamine bicarbonate. The fractions containing product were evaporated, followed by co-evaporation with methanol (2 ). The residue was triturated twice with 100 ml diethylether and dried under vacuum to give a white powder. Yield: 1.24 g, 68% as bis-triethylamine salt. HPLC 98%. 
Fmoc-6-aminohexyldiphosphate: Fmoc-6-aminohexylphosphate (200 mg, 320 μMoles) was co-evaporated twice with anhydrous acetonitrile, then taken up in 2 ml anhydrous DMF. 1,1'-Carbonyldiimidazole (CDI, 207 mg, 1280 μMoles, 4 Eq.) was added and stirred at ambient temperature for 4 hours. Methanol (77 μl, 1920 μMoles) was added and stirred 30 minutes. Tributylamine-H2PO4 (3200 μMoles, 10 Eq.), prepared by mixing equimolar amounts of tributylamine and 85% phosphoric acid followed by co-evaporation 3 times with anhydrous acetonitrile, was dissolved in 4 ml anhydrous DMF and added to the reaction. The reaction mixture was stirred 16 hours. HPLC showed 3% Fmoc-aminohexylphosphate remaining. The reaction mixture was diluted to 50 ml with 0.1M TEAB, and was purified by RP HPLC on a Waters Xterra C18 RP 30 100 column using an acetonitrile gradient in 0.1M triethylamine bicarbonate. The fractions containing product were evaporated, followed by co-evaporation with methanol (2 ). The residue was co-evaporated with anhydrous acetonitrile. Yield: 186 mg, 73% as tris-TEA salt. HPLC 96%. 
Aminohexyl-dG5P: Fmoc-6-aminohexyldiphosphate (186 mg, 233 μMoles) was co-evaporated twice with anhydrous acetonitrile, then taken up in 3ml anhydrous DMF. CDI (150 mg, 930 μMoles, 4 Eq.) was added and stirred at ambient temperature for 4 hours. Methanol (56 μl, 1400 μMoles) was added and stirred 30 minutes. dGTP (TEA salt, 350 μMoles, 1.5 Eq.) was co-evaporated 3 times with anhydrous acetonitrile and suspended in 2 ml anhydrous DMF. The Fmoc-aminohexyldiphosphoimidazolate reaction was added to the dGTP solution followed by anhydrous MgCl2 (3500 μMoles, 333 mg, 10 Eq.). The reaction was stirred 18 hours. HPLC showed 28% of the Fmoc-aminohexyldiphosphate converted to 
A p p e n d i x  C :  N u c l e o t i d e  S y n t h e s i s  
 
 
151 
 
Fmoc-aminohexyl-dG5P. The reaction mixture was diluted to 125 ml with 0.1M TEAB, and was purified by RP HPLC on a Waters Xterra C18 RP 30 100 column using an acetonitrile gradient in 0.1M triethylamine bicarbonate. The fractions containing product were evaporated, followed by co-evaporation with methanol (2 ). The residue was taken up in 20 ml 10% TEA/water and stirred 16 hours to remove the Fmoc protecting group from the amine on the linker. Triethylamine was evaporated, water was added to 25 ml and the solution was extracted 3 times with 25 ml diethyl ether. The product was purified from the aqueous layer by anion exchange chromatography on Q sepharose FF using a TEAB gradient. Yield 42 μMoles, 18%, HPLC 98%. 
Alexa Fluor 488-aminohexyl-dG5P (A488-dG5P): Aminohexyl-dG5P (1 μMole) was dissolved in 0.05 M NaHCO3 pH 8.7 (200 μl) and was added to 1 mg Alexa Fluor 488-TFP ester (Invitrogen, Carlsbad, CA, USA). The mixture was briefly sonicated. After 4 hours, HPLC showed no active ester remaining. The product was identified by characteristic PDA scan. The compound was purified by IEX on Q sepharose FF with a TEAB gradient. The product was further purified by RP HPLC on a Waters Xterra RP C18 19 100 column using an acetonitrile gradient in 0.1M TEAB. The fractions containing pure product were evaporated, followed by co-evaporation with methanol (2 ). The residue was dissolved in water and was quantitated by UV-Vis spectrophotometry. Yield 370 nMoles 37%, HPLC 99%. The other dNTPs were derivatized with Alexa Fluor 633 NHS ester (aminohexyl-dA5P), Alexa Fluor 680 NHS ester (aminohexyl-dC5P), and Alexa Fluor 568 NHS ester (aminohexyl-dT5P). 
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Synthesis Scheme:  
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Appendix D:  
Equipment Specifications  
 
D.1 Microscopes and Peripherals 
D.2 EMCCD Cameras 
D.3 Nanopositioning stages 
D.4 Signal Processing Servers 
D.5 Reassembly Servers 
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Olympus IX71 Inverted Research Microscope 
 
 
 
  
 
 
 
  
 Objective Lens UPLSAPO 60XW 
 
 
à Plan apochromat 
à Water immersion 
à NA = 1.20 
à WD = 0.28 mm  Illumination Source U-LH100HGAPO Mercury Lamp 
  à Aspherical optics à Apochromatic lens 
à Average lamp life: 300 hours  Mirror/Filter Unit U-MWIB2 
Unit Price $30,000 
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Andor iXon EM+ DU-897 Back-Illuminated EMCCD 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
  Active Pixels 512 x 512 Pixel Size 16 µm Image area 8.2 x 8.2 mm Pixel Well Depth 160,000 (max 220,000) Gain Register PWD 800,000 Readout Rate 10 MHz (max) Frame Rate 31 fps QE at 600 nm 95% Unit Price $32,500 
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PI P-587 6-Axis Piezo Stage with E-710.6CD Digital Controller 
 
 
  Active Axes X, Y, Z, θX, θY, θZ Max Travel (X, Y, Z) 800,  800, 200 µm Max Angle ( θX, θY, θZ) ±0.5, ±0.5, ±0.5 mrad Open/Closed Loop Resolution (X, Y) 0.9/2.2 nm Open/Closed Loop Resolution (Z) 0.4/0.7 nm Open/Closed Loop Resolution (θX, θY) 0.05/0.1 mrad Open/Closed Loop Resolution (θZ) 0.1/0.3 mrad Automation Auto-Alignment with CCD Feedback Unit Price $72,000 
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IBM System x3450 79483CX (Signal Processing Server) 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 Processor (CPU) Quad-Core Intel Xeon E5462 Processor Speed 2.80 GHz CPUs 2 Front Side Bus 1 GHz Internal L2 Cache 12 MB RAM 8 GB (800 MHz DDR2) Hard Disk 250 GB, 7200 RPM SATA II Communications Integrated Dual Gigabit Ethernet Form Factor 1U Rack Unit Price $4,000 
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IBM System p560 Express 8234-EMA2 (Reassembly Server) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 Processor (CPU) 8-Core IBM POWER6 Processor Speed 3.6 GHz CPUs 1 Front Side Bus 1 GHz Int. L2/L3 Cache 8 MB / 32 MB RAM 8 GB (800 MHz DDR2) Hard Disk 2 x 146 GB, 15,000 RPM SAS Communications Integrated Dual Gigabit Ethernet Form Factor 4U Rack Unit Price $70,650 
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Appendix E:  
MATLAB Simulation Code 
 
E.1 Program Framework 
E.2 Local Alignment 
E.3 Vote Counting 
E.4 Base Assignment 
E.5 Representative Sensitivity Analysis 
E.6 Dual-Camera Peak Identification 
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Program Framework with Genome Generation Routine 
 
1  function [finalerrorrate snpgenome finalgenome] = genome(genlength,delrate,errorrate,mult) 
2 
3  clear snpgenome finalgenome votefrac maxm index errorloc errorpos error half snppos ... 
4  fragcell alignment score start counter finalerrorrate 
5 
6  % -- Set sequence constants -- % 
7  fragmean = 1000; 
8  fragstdev = 250; 
9  snprate = 1/1000; 
10 
11  % -- Set alignment parameters -- % 
12  gapo = 4; 
13  gape = 21; 
14 
15  % -- Set counter variables -- % 
16  fragind = 1; 
17  dels = 0; 
18  errs = 0; 
19  snps = 0; 
20 
21  % -- Estimate size of fragment library cell array -- % 
22  fragcell = cell(1,round(length(tmv)*mult/(1.2*fragmean))); 
23 
24  % -- Preallocate vote counting matrices -- % 
25  Avotecount = zeros(1,genlength); 
26  Cvotecount = zeros(1,genlength); 
27  Tvotecount = zeros(1,genlength); 
28  Gvotecount = zeros(1,genlength); 
29  Xvotecount = zeros(1,genlength); 
30  sumcount = zeros(1,genlength); 
31  votefrac = zeros(5,genlength); 
32 
33  % -- Preallocate error analysis cell arrays -- % 
34  half = cell(0,0); 
35  error = cell(0,0); 
36  errorpos = cell(1,genlength); 
37  errorloc = cell(0,0); 
38 
39  % -- Generate reference (consensus) genome -- % 
40  tmv = randseq(genlength); 
41  tmv = nt2int(tmv); 
42 
43 
44  %%%%%%%%% 
45  %SNP Insertion% 
46  %%%%%%%%% 
47 
48  snplambda = genlength*snprate; 
49  m = -round((5*snplambda)); 
50  snppos = cell(0,genlength); 
51  snpgenome = tmv; 
52 
53  while m <= genlength 
54   clear vvv 
55   vvv = round(exprnd(1/snprate)); 
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56    if (vvv + m) <= 0 
57     m = m + vvv; 
58    elseif ((vvv + m) > 0) 
59     if (vvv+m) < genlength 
60      uuu = unidrnd(4); 
61      snpgenome(m+vvv) = uuu; 
62      snppos{1,m+vvv} = 1; 
63      m = m + vvv; 
64      snps = snps + 1; 
65     else 
66      m = m + vvv; 
67     end 
68    end 
69  end 
70 
71  genlength = length(snpgenome); 
72 
73 
74  %%%%%%%%% 
75  %Fragmentation% 
76  %%%%%%%%% 
77 
78 length1 = 0; 
79 
80  while length1 <= (mult*genlength) 
81   lastcut = 1; 
82   while (lastcut < genlength) 
83    ttt = unidrnd(50); 
84    fraglength = round(normrnd(fragmean,fragstdev)); 
85    cutsite = fraglength + lastcut; 
86    if ttt == 1 
87     if (cutsite >= genlength) 
88      fragcell{1,fragind} = snpgenome(1,lastcut:genlength); 
89      fragind = fragind+1; 
90     else 
91      fragcell{1,fragind} = snpgenome(1,lastcut:cutsite); 
92      fragind = fragind+1; 
93     end 
94    else 
95     lastcut = cutsite; 
96    end 
97   end 
98   length2 = zeros(1,mult*1.5*genlength/fragmean); 
99 
100   for k = 1:length(fragcell) 
101    length2(1,k) = length(fragcell{1,k}); 
102   end 
103 
104   length1 = sum(length2(1,:)); 
105  end 
106 
107  fragkeep = length(fragcell); 
108 
109 
110  %%%%%%%%% 
111  %Error Insertion% 
112  %%%%%%%%% 
113 
114  for n = 1:fragind-1 
115 
116   errorlambda = length(fragcell{1,n})*errorrate; 
117   m = -round((5*errorlambda)); 
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118   errorfrag = fragcell{1,n}; 
119 
120   while m <= length(fragcell{1,n}) 
121    clear vvv 
122    vvv = round(exprnd(1/errorrate)); 
123    if (vvv + m) <= 0 
124     m = m + vvv; 
125    elseif ((vvv + m) > 0) 
126     if (vvv+m) < length(fragcell{1,n}) 
127      uuu = unidrnd(4); 
128      errorfrag(1,(m+vvv)) = uuu; 
129      m = m + vvv; 
130      errs = errs + 1; 
131     else 
132      m = m + vvv; 
133     end 
134    end 
135   end 
136  fragcell{1,n} = errorfrag(1,:); 
137  end 
138 
139 
140  %%%%%%%%%%% 
141  %Deletion Insertion% 
142  %%%%%%%%%%% 
143 
144  for n = 1:fragind-1 
145 
146   k = 1; 
147   uuu = poissrnd(delrate*length(fragcell{1,n})); 
148   delnum = zeros(1,uuu); 
149   fragchar1 = fragcell{1,n}; 
150 
151   while k <= uuu+1 
152    gam = round(gamrnd(k,1/delrate)); 
153    if gam <= length(fragchar1) 
154     delnum(1,k) = gam; 
155     k = k+1; 
156    else 
157     k = k+1; 
158    end 
159   end 
160 
161   delnum = sort(delnum(1,:)); 
162   delfrag = []; 
163 
164   i = 1; 
165   k = 1; 
166   m = 1; 
167 
168   while i <= length(fragchar1) 
169    if k < length(delnum) 
170     if delnum(1,k) == i 
171      k = k + 1; 
172      i = i + 1; 
173      dels = dels + 1; 
174     else 
175      delfrag(1,m) = fragchar1(1,i); 
176      m = m + 1; 
177      i = i + 1; 
178     end 
179    else 
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180     delfrag(1,m) = fragchar1(1,i); 
181     m = m + 1; 
182     i = i + 1; 
183    end 
184   end 
185   fragcell{1,n} = delfrag; 
186  end 
187 
188 
189  %%%%%%%%%% 
190  %Local Alignment% 
191  %%%%%%%%%% 
192 
193  [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ... 
194   localalign1(Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount,... 
195    fragkeep,fragcell,tmv,gapo,gape,genlength); 
196 
197 
198  %%%%%%%%%%% 
199  %Base Assignment% 
200  %%%%%%%%%%% 
201 
202  [finalgenome snpgenome] = baseassign1(snpgenome,genlength,Avotecount,... 
203   Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount,votefrac); 
204 
205 
206  %%%%%%%%%% 
207  %Error Evaluation% 
208  %%%%%%%%%% 
209 
210  % -- Count sites with less than 3-fold coverage -- % 
211  for n = 1:genlength 
212   if sumcount(1,n) == 2 
213    half{1,n} = n; 
214   else 
215   end 
216  end 
217 
218  % -- Compare final genome to true sequence -- % 
219  %    Determine number and position of errors 
220  for n = 1:genlength 
221   errorpos{1,n} = snpgenome(n) - finalgenome(n); 
222  end 
223 
224  k = 1; 
225 
226  for n = 1:genlength 
227   if errorpos{1,n} ~= 0 
228    error{1,k} = 1; 
229    k = k+1; 
230   end 
231  end 
232 
233  % -- Calculate actual coverage multiplicity -- % 
234  multact = length1/genlength; 
235 
236  % -- Calculate error rate in ppm -- % 
237  finalerrorrate = 1000000*(length(error)/genlength); 
238  end 
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Local Alignment Subroutine 
 
 
1  function [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ... 
2    localalign (Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount, ... 
3     fragkeep,fragcell,tmv,gapo,gape,genlength) 
5  for n = 1:fragkeep-1 
6 
7   if length(fragcell{1,n}) > 1 
8 
9   % -- A single fragment is selected from the fragment library -- % 
10    frag = fragcell{1,n}; 
11    length3 = length(frag); 
12 
13   % -- A shorter fragment is created from the first 10 bases -- % 
14    if length3 > 10 
15     short = frag(1:10); 
16    else 
17     short = frag; 
18    end 
19   
20   % -- This short fragment is aligned with the reference genome, recording starting point-- % 
21   [scorevalue1 alignvalue1 startvalue] = swalign(short, tmv,... 
22   'alphabet','nt','gapopen',gapo,'extendgap',gape); 
23 
24    startvalue = startvalue(2,1); 
25 
26   if startvalue<=1 
27    incr1 = 0; 
28    startvalue = 1; 
29   else 
30     incr1 = 1; 
31   end 
32 
33    if genlength-startvalue<=(20+length3) 
34     incr2 = genlength-startvalue-length3; 
35    elseif genlength-startvalue>(20+length3) 
36     incr2 = 20; 
37    end 
38    
39  % -- The full fragment is aligned to the stretch of reference genome immediately after  the starting point -- % 
40 [scorevalue alignvalue startvalue1] = swalign(frag,tmv((startvalue-incr1):startvalue+length3+incr2),... 
41  'alphabet','nt','gapopen',gapo,'extendgap',gape); 
42 
43   alignseq = nt2int(alignvalue(1,:)); 
44 
45 
46   % -- The base position votes are counted before moving to the next fragment -- % 
47  [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = votecount(genlength, ... 
48  startvalue,alignseq,Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount); 
49 
50  end 
51 end 
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Vote-Counting Subroutine 
 
 
1  function [Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,sumcount] = ... 
2   votecount(genlength,startvalue,alignseq,Avotecount, Cvotecount, ... 
3    Gvotecount,Tvotecount,Xvotecount,sumcount) 
4 
5  % -- The aligned sequences are received from the alignment routine -- % 
6  for k = 1:length(alignseq) 
7 
8   % -- Each base is identified, indexed, and counted -- % 
9   if startvalue+k-1<=genlength 
10 
11    if alignseq(1,k) == 1 
12     Avotecount(1,startvalue+k-1) = Avotecount(1,startvalue+k-1) + 1; 
13 
14    elseif alignseq(1,k) == 2 
15     Cvotecount(1,startvalue+k-1) = Cvotecount(1,startvalue+k-1) + 1; 
16 
17    elseif alignseq(1,k) == 4 
18     Tvotecount(1,startvalue+k-1) = Tvotecount(1,startvalue+k-1) + 1; 
19 
20    elseif alignseq(1,k) == 3 
21     Gvotecount(1,startvalue+k-1) = Gvotecount(1,startvalue+k-1) + 1; 
22 
23    else 
24     Xvotecount(1,startvalue+k-1) = Xvotecount(1,startvalue+k-1) + 1; 
25    end 
26 
27   end 
28  end 
29 
30  % -- Total votes at each position are computed for the assignment subroutine -- % 
31  sumcount(1,:) = Avotecount(1,:) + Cvotecount(1,:) + Tvotecount(1,:) + Gvotecount(1,:); 
32 
33  end 
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Base Assignment Subroutine 
 
1  function [finalgenome snpgenome] = baseassign1(snpgenome,genlength,... 
2   Avotecount,Cvotecount,Gvotecount,Tvotecount,Xvotecount,... 
3    sumcount,votefrac) 
4 
5  % -- Counts at each position are converted to proportions -- % 
6 
7  votefrac(1,1:genlength) = Avotecount(1,1:genlength)./sumcount(1,1:genlength); 
8 
9  votefrac(2,1:genlength) = Cvotecount(1,1:genlength)./sumcount(1,1:genlength); 
10 
11  votefrac(4,1:genlength) = Tvotecount(1,1:genlength)./sumcount(1,1:genlength); 
12 
13  votefrac(3,1:genlength) = Gvotecount(1,1:genlength)./sumcount(1,1:genlength); 
14 
15  votefrac(5,1:genlength) = Xvotecount(1,1:genlength)./sumcount(1,1:genlength); 
16 
17   % -- The the index of the highest vote proportion determines the base assignment -- % 
18 
19   [maxm index] = max(votefrac,[],1); 
20 
21  % -- Finalgenome (computed) and snpgenome (true) are converted to nucleotides -- % 
22 
23  finalgenome = int2nt(index); 
24  snpgenome = int2nt(snpgenome); 
25 
26  end 
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Representative Sensitivity Analysis Script (for Deletion Rate) 
 
 
1  % -- Set sequence constants -- % 
2  genlength = 20000; 
3  errorrate = .001; 
4  mult = 9; 
5 
6  % -- Create matrix of deletion frequencies to be tested -- % 
7  deltest(1,1)= 0.001; 
8  deltest(1,2)= 0.005; 
9  deltest(1,3)= 0.01; 
10  deltest(1,4)= 0.05; 
11  deltest(1,5)= 0.1; 
12  deltest(1,6)= 0.3; 
13 
14  % -- Preallocate arrays -- % 
15  errorc = cell(0,0); 
16  analysis = zeros(length(deltest),7); 
17  l = 1; 
18 
19  trials = 120; 
20  delrate = deltest(1,1); 
21  % -- Test 'm' levels of deletion frequencies with a sample size of 'trials' at each level -- % 
23  for m = 1:length(deltest) 
24 
25   totalerrorrate = zeros(trials,6); 
26    for n = 1:trials 
27 
28    [t1 t2 finalerrorrate snpgenome finalgenome] = genome(genlength,delrate,errorrate,mult); 
29 
30    % -- Record computing time and overall error rate for each trial -- % 
31    totalerrorrate(n,2) = t1; 
32    totalerrorrate(n,3) = t2; 
33    totalerrorrate(n,4) = finalerrorrate; 
34 
35    % -- Record the value and position of each error -- % 
36    for q = 1:length(snpgenome) 
37     if snpgenome(q) - finalgenome(q) ~= 0 
38      errorc{l,1} = q; 
39      errorc{l,2} = snpgenome(q); 
40      errorc{l,3} = finalgenome(q); 
41      l = l+1; 
42     end 
43    end 
44   end 
45 
46   % -- Calculate means and standard deviations for each level of deletion frequency -- % 
47   analysis(m+1,1) = 1/delrate; 
48   analysis(m+1,2) = sum(totalerrorrate(1:trials,2))/trials; 
49   analysis(m+1,3) = std(totalerrorrate(1:trials,2)); 
50   analysis(m+1,4) = sum(totalerrorrate(1:trials,3))/trials; 
51   analysis(m+1,5) = std(totalerrorrate(1:trials,3)); 
52   analysis(m+1,6) = sum(totalerrorrate(1:trials,4))/trials; 
53   analysis(m+1,7) = std(totalerrorrate(1:trials,4)); 
54   delrate = deltest(1,m); 
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Monte Carlo Simulation for Dual Camera Peak Detection 
 
 
1 % Monte Carlo Simulation for Dual Camera Peak Detection 
2 % Basic Equation C2/C1- denotes Intensity reading in camera 2 vs. Intensity 
3 % reading for camera 1. 
4 % 
5 %--------------------------------------------------------------------- 
6 % Generating n samples for a normal distribution for the wavelegth 
7 % intensities picked up by each camera: 
8 %   ca_cb= (randn(n,1)*std)+mean; 
9 %   a is the camera number 
10 %  b is the peak corresponding to the wavelength 
11 %   std is the standard deviation 
12 %   mean is the mean 
13  n = 100000;%------number of iterations 
14  c1_1 = ( randn(n,1)*409.1812)+24198; 
15  c2_1 = ( randn(n,1)*3.821595)+226; 
16  c1_2 = ( randn(n,1)*395.1607)+28178; 
17  c2_2 = ( randn(n,1)*25.25674)+1801; 
18  c1_3 = ( randn(n,1)*10.363)+548; 
19  c2_3 = ( randn(n,1)*476.074)+25175; 
20  c1_4 = ( randn(n,1)*1.675957)+110; 
21  c2_4 = ( randn(n,1)*476.9316)+31303; 
22 %---------------------------------------------------------------------- 
23 % Simulation run for each peak 
24  peak1 = c2_1./c1_1; 
25  peak2 = c2_2./c1_2; 
26  peak3 = c2_3./c1_3; 
27  peak4 = c2_4./c1_4; 
28 %---------------------------------------------------------------------- 
29 % Plotting the Histograms 
30  [n1, xout1] = hist(log(peak1), 50); 
31  [n2, xout2] = hist(log(peak2), 50); 
32  [n3, xout3] = hist(log(peak3), 50); 
33  [n4, xout4] = hist(log(peak4), 50); 
34 
35  plot(xout1, n1,'r', xout2, n2, 'g',xout3, n3, 'b', xout4, n4, 'm'); 
36 
37 %---------------------------------------------------------------------- 
38 % Output for each peak 
39  peak1_mean = mean(peak1) 
40  peak1_std = std(peak1) 
41  peak1_err = peak1_std/n^(0.5)% Finds standard error. 
42 
43  peak2_mean = mean(peak2) 
44  peak2_std = std(peak2) 
45  peak2_err = peak2_std/n^(0.5) 
46  
47  peak3_mean = mean(peak3) 
48  peak3_std = std(peak3) 
49  peak3_err = peak3_std/n^(0.5) 
50 
51  peak4_mean = mean(peak4) 
52  peak4_std = std(peak4) 
53  peak4_err = peak4_std/n^(0.5) 
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Appendix F: 
Financial Pro Forma 
F.1 Case 1 
F.2 Case 2 
F.3 Case 3 
F.4 Case 4 
F.5 Case 5 
F.6 Case 6 
F.7 Case 7 
F.8 Case 8 
F.9 Case 9 
F.10 Case 10 
F.11 Case 11 
F.12 Case 12 
F.13 Growth Case 
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